Theoretical Review

ROLE OF GABA IN ANXIETY AND DEPRESSION

Allan V. Kalueff, Ph.D.[1] and David J. Nutt, M.D.[2]*

This review assesses the parallel data on the role of gamma-aminobutyric acid (GABA) in depression and anxiety. We review historical and new data from both animal and human experimentation which have helped define the key role for this transmitter in both these mental pathologies. By exploring the overlap in these conditions in terms of GABAergic neurochemistry, neurogenetics, brain circuitry, and pharmacology, we develop a theory that the two conditions are intrinsically interrelated. The role of GABAergic agents in demonstrating this interrelationship and in pointing the way to future research is discussed. Depression Anxiety 24:495–517, 2007. Published 2006 Wiley-Liss, Inc.[†]

INTRODUCTION

STRESS, ANXIETY, AND DEPRESSION

Stress plays the main role in the pathogenesis of many mental disorders [Lopez et al., 1999], with anxiety and depression being the most common outcomes of stress in humans and animals [Nutt, 2000, 2001]. Anxiety is a psychiatric disorder associated with excessive and pointless worries, motor tension, and fatigue [Nutt, 2005]. Several different subtypes of anxiety include general anxiety disorder, panic disorder, social anxiety, agoraphobia, posttraumatic stress disorder, and obsessive-compulsive disorder [Clement and Chapouthier, 1998; Nutt, 2005]. Depression is a complex heterogeneous disorder with a wide spectrum of anomalies (such as depressed mood, anhedonia, sleep disorders, fatigue and loss of energy, lack of concentration, low self-esteem, negative thinking, and suicidality) and unclear pathogenesis [Cryan et al., 2002; Wong and Licinio, 2004].

Being extremely debilitating, multifaceted psychiatric illnesses, anxiety and depression have a major impact on the quality of life [Rapaport et al., 2005]. In addition, the prevalence of both disorders is on the increase, especially in the young, and they show considerable overlapping and co-occurrence [Freeman et al., 2002; Nutt, 2005]. Many symptoms of anxiety and depression are similar, and mild anxiety can be difficult to distinguish from mild depression. Depression is common in anxiety patients and anxiety is often

reported in depressed patients, both being predictors of poor outcome [Nutt et al., 2002].

Over the past decades there has been intensive study of a variety of neurobiological mechanisms that underlie depression and anxiety [Clement and Chapouthier, 1998; Sundstrom-Poromaa et al., 2003]. Unipolar disorders have been reported to be more frequently comorbid with anxiety than bipolar disorders, suggesting that anxiety and major depression have a common genetic origin [in Nutt, 2001]. Numerous data indicate that generalized anxiety and depression share their genetic determinants but have partly different environmental determinants [Kendler

[1]Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland
[2]University of Bristol Psychopharmacology Unit, School of Medical Sciences, Bristol, United Kingdom

*Correspondence to: David J. Nutt, MD, Professor of Psychopharmacology, University of Bristol, Psychopharmacology Unit, School of Medical Sciences, Bristol BS8 1TD, UK. E-mail: David.J.Nutt@bristol.ac.uk

[†]This article is a US Government work and, as such, is in the public domain in the United States of America.

et al., 1986, 1987; Roy et al., 1995]. The fact that the symptoms of anxiety and depression may respond to the same treatments support the possibility of a common neurobiological dysfunction, although the exact neurobiological mechanisms behind anxiety and depression have not yet been fully elucidated [Nutt et al., 2002]. It is now becoming recognized that multidisciplinary approaches are necessary to understand the nature of these disorders, and without a knowledge of both clinical and biological aspects of anxiety and depression, it is impossible to offer effective treatment strategies.

Dysfunction of the central gamma-aminobutyric (GABA) system has long been associated with anxiety spectrum disorders [Nutt and Malizia, 2001; Lydiard, 2003; Nemeroff, 2003]. In both human and animal studies, positive modulators of GABA receptors generally possess anxiolytic activity, while negative modulators produce anxiogenic-like effects [Kalueff

and Nutt, 1996; Nutt, 2001]. Consistent with this, various GABA analogs and agents affecting transmitter metabolism to enhance GABAergic tone (e.g., valproate, vigabatrin, and tiagabine) have also been reported to exert anxiolytic effects [Lang and de Angelis, 2003; Nemeroff, 2003; Rosenthal, 2003; Stahl, 2004].

For years, a focus on catecholaminergic mechanisms of depression dominated biological psychiatry. However, a large body of clinical and preclinical literature is now available to support the role of GABA in mood disorders (Tables 1, 2). As such, it is now timely to consider the GABAergic contribution not only to anxiety but also depression disorders [Krystal et al., 2002; Chang et al., 2003; Leung and Xue, 2003]. Here we incorporate recent findings on the GABAergic system in anxiety and depression in order to discuss GABAergic alterations in both psychopathologies and outline possible directions for the search for novel effective medications.

TABLE 1. Effects on depression produced by different GABAergic anxiolytic drugs

| Drugs | Effects on depression | | Depression-like behaviors in animal models (see Table 4) |
	Clinical data	Key references	
GABA analogs and agents affecting transmitter metabolism			
Valproate	↓	Gilmer, 2001; Gajwani et al., 2005[a]	↓
Amino-oxyacetic acid	?		↓
Vigabatrin	↓	Ring et al., 1993; Besag et al., 2001[b]	?
Gabapentin	↓	Ghaemi et al., 1998; Altshuler et al., 1999; Obrocea et al., 2002; Fong et al., 2003	?
Tiagabine	↓	Post et al., 1998; Shelton, 2003	?
Beta-phenyl-GABA	↓	Lapin, 2001	↓
GABA agonists			
GABA, muscimol, progabide[c]	?	Lloyd et al., 1983; Bartholini, 1984	↓
Benzodiazepines	↓	Lemoine et al., 1991; Birkenhager et al., 1995; Petty et al., 1995; Wang and Ketter, 2005	0, ↓
Ethanol	↓	O'Sullivan, 1984; Khisti et al., 2002[d]	↓
Neurosteroid agonists	↓		↓
Allopregnanolone, progesterone[e]		Dubrovsky, 2005; Eser et al., 2006a,b	

↓ means reduction of depression. 0 = no effects, ? = no data.
[a]Also produces mood stabilizing effects [Nestler et al., 2002].
[b]Causes the opposite effect after long-term treatment.
[c]Progabide has agonistic properties at both GABA-A and GABA-B receptors.
[d]Antidepressant action of ethanol in humans is known only for acute mild doses; chronic ethanol consumption (alcoholism) decreases ethanol AD action and is associated with increased depression and anxiety [Enoch, 2003].
[e]Note that progesterone is not a direct modulator of GABA-A receptors, and acts via own progesterone receptors or as an antagonist to brain sigma and nicotinic receptors [reviewed in Bullock et al., 1997; Maurice, 2004]. Recent studies [Reddy et al., 2005] found that anxiolytic effects of progesterone are preserved in mutant mice lacking progesterone receptors due to its conversion to allopregnanolone, suggesting that its behavioral effects are due to allopregnanolone modulation of GABA-A receptors.

TABLE 2. Summary of the effects of depression on GABAergic system

Clinical data	Preclinical data
Reduced level of GABA in plasma [Petty et al., 1990, 1998], CSF and brain [Sundman-Eriksson and Alard, 2002; Sanacora et al., 1999, 2000; Kugaya et al., 2003; Chang et al., 2003]. Reduction in the number of GABA neurons in orbitofrontal cortex of depressed patients [Rajkowska et al., 1999]. Lower cortical GABA in postpartum depression [Epperson et al., 2006].	Reduced GABA-activated chloride influx in LH model in rats [Drugan et al., 1989]. Decreased GABA release in hippocampus in LH model [Petty and Sherman, 1981; Shiah and Yatham, 1998] and in cortex, hippocampus, nucleus accumbens and brainstem in FST in rats and mice [Borsini et al., 1988; Gomez et al., 2003; Briones-Aranda et al., 2005]. Increased brain GABA-A receptor density in OB and LH models in rats [Dennis et al., 1984; Kram et al., 2000].
Reduced plasma and CSF levels of GABA-active steroid agonists; increases concentration of steroid antagonists [George et al., 1994; see also Rupprecht, 2003; Spivak, 2000; and Lydiard, 2003].[a]	Reduced cortex GABA-active steroid allopregnanolone after social isolation in mice [see Rupprecht, 2003 for details]. Region-specific dysregulation of allopregnanolone in OB in rats [Uzunova et al., 2003, 2004].
Reduced benzodiazepine binding in frontal and orbitotemporal cortex in a patient with treatment-resistant depression and anxiety [Kosel et al., 2004]. Increased CSF concentration of DBI [Barbaccia et al., 1986; Roy, 1991; Sandford et al., 2000], including anxiety/depressive patients [Guidotti, 1991; but see George et al., 1994] and suicide depression victims [Rochet et al., 1998].	Decreased benzodiazepine binding after FST in rat hypothalamus and amygdala and in chronic stress model in frontal cortex, hippocampus, and hypothalamus [Medina et al., 1983; Briones-Aranda et al., 2005]. Increased brain DBI expression after long-term stress in mice [Katsura et al., 2002; reversed by antidepressant treatment].[b]
	Increased muscimol binding in rats not susceptible to behavioral despair [Drugan et al., 1993].

FST, forced swim (Porsolt's) test; TST, tail suspension test; LH, learned helplessness model; OB, olfactory bulbectomy; DBI, diazepam-binding inhibitor; CSF, cerebrospinal fluid.
[a]See also similar data in Daly et al. [2001]; Reddy [2003]; Vaiva et al. [2003] for premenstrual and posttraumatic stress syndromes.
[b]See, however, Dong et al. [1999] reporting reduced DBI mRNA in mouse hypothalamus after social isolation stress.

ANIMAL MODELS OF ANXIETY AND DEPRESSION

The present article aims to present a balanced review where clinical findings will be compared with animal experimentation data. The growing number of experimental models is now extensively used to search for novel therapeutic agents and dissect the neurobiological mechanisms of brain pathogenesis [Geyer and Markou, 1995; McKinney, 2004]. But can we model human anxiety and depression in animals? There are several traditional models of anxiety, including paradigms based on exploration (open field, holeboard, elevated plus maze, light-dark, social interaction, mirror chamber) and conditioned or unconditioned threat responses [reviewed in Rodgers, 1997; Crawley, 1999, 2000; Flint, 2002, 2003; Carobrez and Bertoglio, 2005]. The most popular experimental models of depression include "despair" paradigms (such as Porsolt's forced swim [FST], Steru's tail suspension [TST] tests, and learned helplessness [LH]), as well as olfactory bulbectomy (OB), maternal/social deprivation, and "anhedonic" chronic mild stress (CMS) [see Ho et al., 2002; Nestler et al., 2002; Cryan and Mombereau, 2004; Cryan et al., 2005; Cryan and Holmes, 2005, for details]. There are, however, problems with these models, which have to be critically discussed before claiming parallels between animal and human brain disorders.

First, since many aspects of human anxiety and depression psychopathology are poorly understood today, the important question of what exactly to model remains open [see, e.g., Argyropoulos and Nutt, 1997]. Clearly, there are certain features of human behavior and cognition that cannot be fully reproduced in animals, thus contributing to the problem of objective difficulties with translating human symptoms into animal tests [Crawley, 2000; Wong and Licinio, 2004; Cryan and Holmes, 2005]. In addition, animal paradigms usually fail to reproduce complex multi-syndromal human disorders, may show unwanted selectivity to particular neuromediatory systems, or have questionable ability to detect novel compounds with unknown mechanism(s) of action [see Belzung, 2001; Flint, 2003; Cryan and Mombereau, 2004; Cryan et al., 2005, for discussion]. Other problems include conflicting timecourse results (e.g., acute antidepressant effects in some animal models do not match delayed action of these drugs in humans); model's oversensitivity to external (environmental, epigenetic) or internal (genetic) factors; as well as poor reproducibility (e.g., CMS) even within the same laboratory [see Bai et al., 2001; Cryan et al., 2002; Cryan and Mombereau, 2004, for details]. In addition, some of these models may lack specificity [Schechter and Chance, 1979; e.g., failing to discriminate between anxiolytics and antidepressants: Borsini et al., 2002; Rupniak, 2003], while others, being specific, do not target clinically important comorbidity aspects [Crowley and Lucki, 2005]. Overall, this raises the problem of *mimicking* (at a behavioral phenocopy level) vs. *modeling* a "true" psychiatric state, and the problem of behavioral

vs. physiological vs. cognitive components of pathogenesis [Battaglia and Ogliari, 2005]. Also, there should be, but not always recognized, a clear distinction between a model (simulating the disorder as a syndrome) and a test (relatively simple assay targeting specific features of this disorder) [Rupniak, 2003; Crowley and Lucki, 2005; Urani et al., 2005]. Finally, there is a great need for the creation of a new generation of anxiety and depression tests based principally on new theories and approaches [Cryan et al., 2002; Cryan and Mombereau, 2004; Cryan and Holmes, 2005].

Nevertheless, despite all these caveats, animal tests of anxiety and depression have proven to be crucial for biomedical research, including fast high-throughput testing of anxiolytic and antidepressant drugs [Flint, 2003; Wong and Licinio, 2004], assessment of behavioral phenotypes of mutant or transgenic animals [Crawley, 1999, 2000; Flint, 2002; Urani et al., 2005], testing neurobiological hypotheses [Geyer and Markou, 1995], or finding candidate genes for human behavioral disorders [Crowley and Lucki, 2005]. Thus, understanding the potential benefits and weaknesses of animal models may allow us to obtain valid animal experimentation data to parallel and/or complement the available clinical findings, leading to new, effective therapies for anxiety and depression.

GABAERGIC MECHANISMS IN ANXIETY AND DEPRESSION

GABA AND ITS RECEPTORS

GABA is the primary mediator of inhibitory transmission in the mammalian central nervous system [Sieghart, 1995; Sieghart et al., 1999]. It has complex interactions with other neurotransmitter systems and acts through ionotropic A and metabotropic B type receptors, which play important roles in the brain and are a target for a variety of endogenous and exogenous modulators [Nutt and Malizia, 2001; Korpi et al., 2002; Boehm et al., 2004; Mombereau et al., 2004]. GABA-A receptors inhibit neurons and are crucial to controlling brain excitability [Korpi et al., 2002; Chang et al., 2003]. GABA-A receptors are ligand-gated ion channels composed of five subunits from eight families: α (1–6), β (1–3), γ (1–3), δ, ε, π, θ, and ρ (1–3) [Marowsky et al., 2004; Korpi and Sinkkonen, 2006]. The most abundant composition of GABA-A receptor is $2\alpha,2\beta,1\gamma$ [Sieghart, 1995; Sieghart et al., 1999] such as $\alpha1\beta2\gamma2$ (~40% of all GABA-A receptors throughout the brain) or $\alpha2\beta3\gamma2$ (common in the limbic system, cerebral cortex, and striatum, ~20% of all GABA-A receptors) [Rosahl, 2003; Mohler et al., 2004]. Binding of GABA opens up a Cl^- channel, which is part of the protein structure. GABA-A receptors contain binding sites for many positive modulators including barbiturates, benzodiazepines, steroids, and ethanol [Sieghart et al., 1999; Korpi et al., 2002; Olsen et al., 2004].

In addition, these include GABA-A antagonists, neurosteroid antagonists, benzodiazepine inverse agonists, and chloride channel blockers that are negative modulators of GABA-A receptors [reviewed in Sieghart et al., 1995; Belelli and Lambert, 2005; Dubrovsky, 2005].

Though less well understood, GABA-B receptors are thought to modulate the generation of excitatory postsynaptic potentials and long-term potentiation [Chang et al., 2003]. They are formed from two subunits, B1 and B2, each with seven transmembrane-spanning elements that come together to form heterodimers in which both subunits are necessary for the receptor to be functional [Mombereau et al., 2004, 2005]. The B1 subunit binds ligands within its extracellular N-terminus, while the B2 subunit is responsible for receptor trafficking and its interaction with cognate G-protein [reviewed in Ong and Kerr, 2005]. GABA-B receptors are found both presynaptically and postsynaptically. Both GABA-A and -B receptors are shown to be involved in the regulation of many normal and pathological brain mechanisms including sleep, memory, epilepsy, and various emotions [Kalueff and Nutt, 1996; Kalueff, 1997; Mihalek et al., 1999; Chapouthier and Venault, 2002; Brambilla et al., 2003; Leung and Xue, 2003; Vaiva et al., 2004; Cryan and Kaupmann, 2005].

HISTORICAL BACKGROUND AND RECENT FINDINGS

An important role of GABA in mood disorders was first postulated by Emrich et al. [1980], and over the last decades much data has emerged to support the GABAergic theory of depression [Borsini et al., 1988; Lloyd et al., 1985, 1989; Petty, 1995; Shiah and Yatham, 1998]. There are several good recent articles that discuss clinical and experimental data linking GABA to depression [Tunnicliff and Malatunska, 2003; Brambilla et al., 2003; Leung and Xue, 2003]. Briefly, depression is often associated with decreased GABAergic function, while various antidepressant (AD) manipulations tend to increase it; low GABA function is proposed to be an inherited biological marker of vulnerability for depression; positive modulators of GABA-A receptors can have AD actions, while GABA-A negative modulators often produce depression. There is a large body of evidence to confirm that GABAergic anxiolytic drugs do produce AD effects in patients (Table 1). Unfortunately, there is little clinical data on the effects produced by GABAergic anxiogenic drugs (such as GABA-A antagonists, neurosteroid antagonists, benzodiazepine inverse agonists, as well as the chloride channel blockers pentylenetetrazole and picrotoxin), although some clinical cases with depressed features have been noted where pentylenetetrazole was used to activate epileptic foci [see Rodin, 1958, 1970, for review]. There is more evidence for a role of GABA in depression (see Table 2 for details).

In line with clinical observations, there are animal studies also. The pioneering studies of Petty and Sherman [1981] were first to link the GABAergic system to animal depression. Since this time, in many studies a GABA deficit, paralleled by decreased GABA-A receptor activity, was suggested to be a functional correlate of depression [Belozertseva and Andreev, 1997; Kram et al., 2000] (see also Table 2), while AD treatment activated GABAergic functions both in animals and humans (Table 3). In line with GABAergic hypothesis of depression, GABA mimetics were found to possess AD-like properties, while GABA antagonists increase depression in the above animal models [Raghavendra et al., 2000]. Tables 4 and 5 represent a detailed summary of the effects that different GABAergic drugs demonstrate in currently available animal models of depression. Analysis of data presented in Tables 1, 3, and 4 shows that activation of the GABAergic system has both antianxiety and antidepressant effects in animals and humans. In contrast, decreased GABAergic activity consistently correlates with anxiety and depression (Tables 2, 5). Together, this clearly demonstrates the key role that GABA plays in both psychopathologies and indicates that drugs affecting GABA-A receptors may be useful in the treatment of both anxiety and depression.

In contrast to GABA-A receptors (Tables 1,2,3,4,5), the potential role of GABA-B receptors in anxiety and depression is far less understood [Lloyd et al., 1985;

Nakagawa et al., 1996a; Sand et al., 2000; Mombereau et al., 2004, 2005; Cryan and Kaupmann, 2005; Pilc and Nowak, 2005]. For example, the GABA-B agonist baclofen was found to be ineffective in several animal anxiety tests [Umezu, 1999; Dalvi and Rodgers, 1996; Zarrindast et al., 2001], but revealed anxiolytic-like properties (similar to GABA-A agonists) in several other studies [File et al., 1991, 1992; Shephard et al., 1992; Bueno et al., 2005a]. Baclofen was ineffective in the FST depression test, increased learned helplessness, and attenuated the effects of ADs in rats [Nakagawa et al., 1996a,b], but reduced depressiveness and reversed reserpine effects in the FST in mice [Aley and Kulkarni, 1989; see similar data in rats in Hilakivi et al., 1988]. In humans, baclofen showed no clinical effects in one study [Jamous et al., 1994], but exerted anxiolytic effects in posttraumatic patients [Hinderer, 1990] and was effective in treating patients with posttraumatic stress disorder with comorbid anxiety or depression [Drake et al., 2003]. It was also effective on anxiety and depression in alcoholic patients [Krupitskii et al., 1994] but has been reported to worsen depression in several other clinical cases [Post et al., 1991]. Taken together with recent genetic data, reporting increased anxiety and reduced depression-like behavior in mutant mice lacking GABA-B receptor subunits [Cryan and Kaupmann, 2005; Mombereau et al., 2004, 2005], it seems that (unlike GABA-A receptors) the GABA-B receptor system may differen-

TABLE 3. Summary of the effects of antidepressant treatments on GABAergic system

Clinical data	Preclinical data
Increased cortex GABA [Sanacora et al., 2002] in depressed patients after SSRI treatments [see Rupprecht, 2003; Khisti et al., 2000; Uzunova et al., 2003, for reviews].	Elevated hippocampal GABA release after AD treatments in LH model in rats [Petty and Sherman, 1981; Kram et al., 2000]. Elevated cortical GABA after AD treatment in rats [Yang and Shen, 2005]. Increased brainstem GABA-A $\alpha1$, $\alpha3$, $\beta1$, $\beta2$ and $\gamma2$ subunits mRNA levels [Tanay et al., 1996, 2001] and hippocampal GABA-B1 expression [Sands et al., 2004] after chronic AD treatment in rats. Increased Cl^- uptake in submissive rats after AD treatment [Malatynska et al., 1995, 2000]. Chronic (but not acute) AD antagonized behavioral hyperactivity in rats produced by GABAergic inhibition by picrotoxin [Plaznik et al., 1989].
Increased cortex GABA level after electroconvulsive therapy [Sanacora et al., 2003] and SSRI, but not after cognitive behavioral therapy [Sanacora et al., 2003, 2006; Bhagwagar et al., 2004]. Increased cortex GABA level in drug-resistant depressed patients after electroconvulsive therapy [Mervaala et al., 2001].	Elevated striatal GABA level after AD treatment in rats [Gomez et al., 2003]. Increased GABA synthesis in amygdala, hippocampus, lateral septum after selective NE reuptake inhibitors [Herman et al., 2003]. Reduced pentylenetetrazole-activated hippocampal electroencephalogram power in rats after AD treatment [Matsubara et al., 2000].
Recovery from depression increases plasma level of GABA-active steroid agonists allopregnanolone and pregnanolone but decreases concentration of steroid antagonist 3b-hydroxy-5a-pregnan-20-one [Rupprecht, 2003]. Restored allopregnanolone levels in plasma and cerebrospinal fluid in depressed patients after AD treatment [Uzunova et al., 1998, see Khisti et al., 2000; Rupprecht, 2003; and Uzunova et al., 2003 for details].	Increased level of allopregnanolone in rat brain after SSRIs treatment [Uzunov et al., 1996; also see Rupprecht, 2003, for review]. Restored cortical allopregnanolole levels after chronic AD treatment in olfactobulbectomized rats [Uzunova et al., 2004].

Abbreviations as in Table 2. AD, antidepressant; SSRI, selective serotonin reuptake inhibitors; NE, norepinephrin. See also a detailed discussion in Argyropoulos et al. [2000].

TABLE 4. Summary of antidepressant effects produced by GABAergic anxiolytic drugs in animal experimental models

Drugs	Models
Valproate	FST in mice [Fernandez Teruel et al., 1988; Aley and Kulkarni, 1989; Raghavendra et al., 2000]
	Potentiated effects of other ADs in the FST in mice [Szymczyk and Zebrowska-Lupina, 2000]
Amino-oxyacetic acid	FST in rats [Borsini et al., 1986, 1988]
Vigabatrin	Potentiated ADs' effects in the FST in mice [Szymczyk and Zebrowska-Lupina, 2000]
	OB in rats [Kelly et al., 1997]
Beta-phenyl-GABA	Eliminated increase in benzodiazepine receptors produced by the FST in rats [Rago et al., 1990]
GABA	FST in mice, LH in rats [Aley and Kulkarni, 1989; see Kram et al., 2000 for details]
	Potentiated effects of ADs, reversed depressant effects of reserpine in FST in mice [Aley and Kulkarni, 1989]
Muscimol	FST in mice/rats [Aley and Kulkarni, 1989; Borsini et al., 1986; Nakagawa et al., 1996a; Raghavendra et al., 2000]
	Reversed depressant effects of reserpine in FST in mice [Aley and Kulkarni, 1989]
	Potentiated AD effects of ethanol and allopregnanolone in the FST in mice [Hirani et al., 2002; Khisti et al., 2000]
Progabide[a]	AD-like effects in animal tests [Bartholini, 1984]
Diazepam	FST in rats [Nishimura et al., 1989, 1992; but Bourin et al., 1991]
	Reduced muricide in OB in rats [Shibata et al., 1984]
Carbamazepine and oxcarbazepine	FST and LH in rats [Beijamini et al., 1998, Joka et al., 2000]
	Potentiated ADs' effects in the FST in mice [Szymczyk and Zebrowska-Lupina, 2000]
Alprazolam, adinazolam	OB, FST in rats [O'Connor et al., 1985; Flugy et al., 1992]
Pentobarbital	FST in mice [Schechter and Chance, 1979]
Ethanol	FST in mice, acute administration [Hirani et al., 2002][b]
	Attenuated depressant action of cocaine in the FST in rats [Hayase et al., 2002]
Allopregnanolone and progesterone[a]	FST in mice/rats [Khisti et al., 2000; Estrada-Camarena et al., 2002; Rupprecht, 2003]
	Enhanced effects of other ADs in the FST in mice/rats [Estrada-Camarena et al., 2002; Rupprecht, 2003]
	Potentiated AD effects of ethanol in FST in mice [Hirani et al., 2002]
	Sub-antidepressant doses of steroid agonists in the FST in mice reversed depression associated with ethanol withdrawal [Hirani et al., 2002]

Abbreviations as in Tables 2, 3.
[a]See legend to Table 1 for details on progabide and progesterone mechanisms of action.
[b]Note that antidepressant action of ethanol in the FST is reported only for its acute administration; its prolonged consumption produced tolerance to this effect and its withdrawal enhanced behavioral despair and elicited tolerance to antidepressant-like action of acute ethanol [Hirani et al., 2002].

tially affect anxiety and depression, so is most likely not involved in synergetic anxiety–depression pathogenesis [Pilc and Nowak, 2005]. The GABA-B receptor system will therefore not be discussed here in much detail.

GENETIC DATA: GABAERGIC RECEPTORS

It has long been known that genetic factors play a role in the etiology of both anxiety and depression [Kendler et al., 1986, 1987; Finn et al., 2003; Villafuerte and Burmeister, 2003; Gillespie et al., 2004]. A recent study found lowered plasma GABA in depressed patients and their first-degree relatives [Bjork et al., 2001], confirming that GABAergic tone also may be under genetic control. Not surprisingly, neurogenetic approaches (such as genetic polymorphism, quantitative trait loci, microarray, and mutagenesis studies) provide us with new insights into biological psychiatry of GABA-related aspects of these disorders.

GABA-A receptor genes form clusters ([ρ1, ρ2, δ]; [α2, α4, β1, γ1]; [α5, β3, γ3]; [α1, α6, β2, γ2], [α3, θ, ε]) on several chromosomes, whereas two GABA-B receptor (B1, B2) genes have been mapped to two different chromosomes [Hisama et al., 2001; Martin et al., 2001; Boehm et al., 2004; MGI, 2006]. While genes encoding α2, α3, α4, α6, β1, γ1, and γ2 subunits have been associated with anxiety-like behaviors in animals [Vekovisheva, 2003; Rosahl, 2003; Marowsky et al., 2004; Chandra et al., 2005; Gill and Boyle, 2005; Korpi and Sinkkonen, 2006], the association has also been established in animals between α1, α3, α6 genes and depressiveness, and α5 gene and cognitive functions [Crestani et al., 1999; Collinson et al., 2002; Atack et al., 2005]. Multiple genetic loci studies in mice [Yoshikawa et al., 2002] linked animal depressive-like behavior in the FST and TST to GABAergic loci on chromosomes 8 and 11, encoding α1, α6, and γ2 subunits of GABA-A receptors. Recent gene expression studies in rats showed downregulation of both GABA-A and GABA-B genes (encoding α1, α4, α5, α6, γ1, δ, and B1 subunits) in highly anxious PVG hooded (vs. Sprague-Dawley) strains following cat exposure [Wang et al., 2003], as well as reduced expression of α2, γ1, or δ subunits after fear conditioning [Mei et al., 2005], chronic unpredictable stress [Verkuyl et al., 2004], or depression evoked by social confrontation [Kroes et al.,

TABLE 5. Summary of prodepressant effects produced by GABAergic anxiogenic drugs in animal experimental models (all these drugs reduce GABA-A function in one way or another[a])

Drugs	Models
Bicuculline (GABA-A-antagonist)	FST and LH in rats/mice [Petty and Sherman, 1981; Aley and Kulkarni, 1989; Hayase et al., 2002]
	Reversed effects of several AD in the FST in rats [Nakagawa et al., 1996a]
	Reversed AD effects of valproate, ethanol, fengabine and melatonin in the FST and OB in rats/mice [Lloyd et al., 1987; Fernandez Teruel et al., 1988; Raghavendra et al., 2000; Hirani et al., 2002]
FG 7142 (benzodiazepine inverse agonist)	FST in mice [Chopra et al., 1988]
	LH in rats [Drugan et al., 1985; Tunnicliff and Malatynska, 2003]
Ro 15-3505 (benzodiazepine inverse agonist)	FST in rats [Skrebuhhova et al., 1999]
Beta-carboline-3-carboxylic acid methyl (CCM) ester (benzodiazepine inverse agonists)	FST in rats [Nishimura et al., 1989]
	Mice bred for increased sensitivity for CCM show increased depression in the FST and TST [Do-Rego et al., 2002].
Pregnanolone sulphate (Cl⁻ channel closer)	No effects were found in the FST in mice [Urani et al., 2001, but see Reddy, 2003].
Finasteride, trilostane, and indomethazine (inhibitors of the endogenous neurosteroid biosynthesis)	Attenuated AD effects of ethanol in the FST in mice [Hirani et al., 2002].
Picrotoxin (Cl⁻ channel blocker)	FST in mice/rats [Aley and Kulkarni, 1989; Skrebuhhova et al., 1999]
	Reversed effects of muscimol, valproate, and other ADs in the FST and LH in rats [Borsini et al., 1986; Fernandez Teruel et al., 1988; Cannizzaro et al., 1993; see also Tunnicliff and Malatynska, 2003]
	Reversed AD effects of progesterone in FST in rats [Estrada-Camarena et al., 2002]
Pentylenetetrazole (Cl⁻ channel blocker)	FST in rats [Cannizzaro et al., 1993; Skrebuhhova et al., 1999]

Abbreviations as in Tables 2, 3.
[a]See also interesting data on GABA-A receptor antisense nucleotides that attenuate AD-induced Cl⁻ uptake in rats [Malatynska et al., 2000].

2005]. In contrast, chronic antidepressants upregulated α1, α3, β1, β2, and γ2 genes in rat brainstem [Tanay et al., 1996, 2001], while altered anxiety and depression-related behavior was found in mutant mice lacking B1 and B2 receptors [Mombereau et al., 2004, 2005].

A recent human study showed that severe treatment-resistant depression with anxiety was linked to a mutation in the β1 subunit of GABA-A receptor [Kosel et al., 2004]. Positive genetic associations were found between polymorphism in human GABA-A receptor subunits genes and unipolar (α3, α5), bipolar (α1, α3, α5, α6) depression or neuroticism (α6) [Bell et al., 1989; Buckle et al., 1989; Oruc et al., 1997; Papadimitriou et al., 1998; Massat et al., 2002; Yamada et al., 2003; Henkel et al., 2004; Horiuchi et al., 2004; Sen et al., 2004; Korpi and Sinkkonen, 2006] as well as posttraumatic stress disorder with anxiety and depression (β3) or hormonal and autonomic stress response (α6) [Feusner et al., 2001; Uhart et al., 2004]. In line with this, comprehensive genetic linkage studies reported the 5q34 locus (containing a cluster of α, β, and γ GABA-A genes) to be associated with mood disorders [Edenberg et al., 1997], and exonic variants of the B1 receptor gene with panic disorder [Sand et al., 2000]. Recent

microarray study also revealed altered expression of GABA-A (α5, β3, γ2, δ) and GABA-B (B1) receptor genes in cortex of depressed patients [Choudary et al., 2005].

Collectively, these data indicate that both GABA-A and GABA-B genes may be involved in the regulation of anxiety and depression. Despite the fact that we still lack a complete understanding of genes that increase the risk of depression and anxiety [Nestler et al., 2002; Finn et al., 2003; Villafuerte and Burmeister, 2003], these striking data coming from behavioral neurogenetics and clinical studies provide substantial support for the key role that GABA may play in depression and anxiety pathogenesis. This also suggests that manipulations with GABAergic genes in both animals and humans, as well as the use of subunit-specific GABAergic drugs with selective pharmacological profiles [see Atack, 2003, 2005; Whiting, 2003; Atack et al., 2005; Rudolph and Mohler, 2006], may allow us to find new possibilities to cure anxiety and depression.

GABA METABOLISM

In addition to receptor actions, a role in anxiety and depression pathogenesis belongs to factors affecting

GABA metabolism and uptake [Goddard et al., 2004]. For example, glutamic acid decarboxylase (GAD) is a key enzyme of GABA biosynthesis from glutamic acid. Both unipolar and bipolar mood disorders have been found to be associated with polymorphism in the GAD67 gene encoding a 67-kDa isoform of GAD [Lappalainen et al., 2004; Lundorf et al., 2005] responsible for 90% of GABA synthesis from glutamate in the brain. Reduced GABA levels and increased anxiety were found in mice lacking a small 65-kDa isoform of GAD (GAD65) responsible for fine-tuning of GABAergic neurotransmission [Kash et al., 1999; Stork et al., 2000], whereas GAD65 expression was increased by AD reboxetine in septum of stressed rats [Herman et al., 2003]. Recent studies found the link between polymorphism in the GAD65 gene and anxiety-related behavioral inhibition in children [Smoller et al., 2001], while prefrontal cortex and cerebellar GAD65 and GAD67 levels were decreased in depressed patients [Guidotti et al., 2000; Fatemi et al., 2005],

GABA transaminase (GABA-T) is another key enzyme in GABA turnover, which catabolizes GABA. Its inhibitors (such as valproate and vigabatrin) elevate GABA levels, show pronounced anxiolytic effects in various experimental models [Sherif and Oreland, 1995; Lang and de Angelis, 2003], and are able to exert (valproate) consistent AD effects in humans [reviewed in Post, 2004; Rogawski and Loscher, 2004; Gajwani et al., 2005, Zwanzger and Rupprecht, 2005].

Several known GABA transporter proteins (GAT 1–4) and their subtype-specific modulators have also been shown to influence GABAergic signaling [Sundman et al., 1997; Keros and Hablitz, 2005], thus opening the possibility of novel psychotropic GAT-related drugs [Schousboe et al., 2004]. Indeed, GAT-1 inhibitors (such as NO-711 and tiagabine) increase GABA tone and exert predictable anxiolytic effects in animals [Dalvi and Rodgers, 1996; Schmitt and Hiemke, 1999; chronic treatment: Schmitt et al., 2002] and humans [Crane, 2003; Schaller et al., 2004; Connor et al., 2006]. For example, tiagabine was useful to treat treatment-resistant anxiety as well as various anxiety disorders combined with anxiety [reviewed in Zwanzger and Rupprecht, 2005]. Although in a recent study suicidal depression did not correlate with altered GAT-1 binding in frontal cortex and cingulated gyrus [Sundman-Eriksson and Allard, 2002], several clinical studies indicate that GAT inhibitors such as tiagabine may be used as mood stabilizers, indicating their utility in therapy for depression [Kaufman, 1998; Schaffer et al., 2002; Schwartz, 2002] via modulation of central GABAergic system [but see Post, 2004]. Collectively, these findings indicate that both anxiety and depression depend on GABA metabolism, whose imbalance may play a role in their overlapping pathogenesis. Therefore, novel drugs targeting both the activity and expression of enzymes of GABA synthesis and metabolism, as well as GAT [Sarup et al., 2003], may

represent potential interest for antianxiety/antidepressant therapy.

Notably, drugs affecting GABA metabolism may also have additional mechanisms of action, which have to be taken into account. For example, valproate modulates metabolism of γ-hydroxybutyric acid (GHB), a weak agonist at GABA-B receptors [reviewed in Crunelli et al., 2005]. In line with this, the AD phenelzine (effective in therapy of social anxiety and panic disorders in humans) inhibits GABA-T, elevates brain GABA levels, produces anxiolytic-like effects in animals, and also modulates glutamate and catecholamine neurotransmission [reviewed in Yang and Shen, 2005]. Taken together, these data contribute to the complexity of GABAergic and other mechanisms in anxiety and depression, prompting new strategies of therapy targeting simultaneously GABA and other mediator systems (see below).

GABA AND OTHER SUBSTANCES INVOLVED IN ANXIETY AND DEPRESSION

The well-established endocrine abnormalities of depression and anxiety [Erickson et al., 2003] are another important aspect to consider in relation to GABA. For example, neurosteroids modulating GABAergic/benzodiazepine functions may have a potential for the development of new AD drugs [Strohle et al., 1999; Khisti et al., 2000] which at the same time should have an anxiolytic profile [Ungard et al., 2000; Reddy, 2003]. Interestingly, the well-known acute anxiolytic and mood lifting–euphoric action of ethanol may be produced by its direct effects on GABA-A receptors as well as due to modulation of the neurosteroid system [Khisti et al., 2002]. As such, the search for novel drugs binding to ethanol site on GABA-A receptors may be a promising multitarget approach.

On a related point, anxiety and depression have long been associated with alterations in secretion of many hormones including adrenocorticotropic hormone (ACTH), cortisol/corticosterone, corticotropin-releasing hormone (CRH), adrenal catecholamines, oxytocin, prolactin, and rennin [Arborelius et al., 1999; Carrasco and Van de Kar, 2003; Finn et al., 2003]. As summarized by these authors, endogenous and exogenous GABAergic drugs may affect the secretion of some of these hormones. Several benzodiazepine agonist ligands decrease ACTH/corticosterone as well as oxytocin and prolactin responses to stressors [Carrasco and Van de Kar, 2003]. Also, the GABAergic system inhibits stress-induced cortisol secretion as well as CRH liberation into the portal vein [Lopez et al., 1999]. It is therefore possible that in depression a deficiency of endogenous GABA/benzodiazepine ligands (see Table 2) could lead to neuroendocrinological disregulation that contributes to pathogenesis. It also seems possible that correction of stress-induced neuroendocrinological mechanisms by GABAergic

drugs may be a potential therapeutic approach to treat depression and anxiety targeting both "low GABA → high stress" and "high stress → low GABA" pathogenic mechanisms. Perhaps affecting one disorder (e.g., anxiety) through direct anxiolytic action on GABA receptors, some GABAergic drugs may in parallel correct stress-induced neuroendocrine mechanisms. This may not only target the "endocrine" component of the existing anxiety but also aim at the endocrine mechanisms underlying depression. The latter may lead to additional very useful therapeutic effects targeting anxiety/depression disorders and/or their comorbidity caused by neuroendocrine disregulations.

A possible interplay between aversive memories and stress neuroendocrinology outlines a further possibility where GABAergic intervention may be useful to treat anxiety and depression. Treating one disorder (e.g., anxiety) through direct anxiolytic action on GABA receptors, GABAergic drugs may in parallel block recurrent negative memories that not only complicate the existing disorder [Kalueff and Nutt, 1996] but also provoke the other disorder (e.g., depression). The role of negative memories in both anxiety and depression has been reported extensively in the literature [Davidson, 2002]. In addition to the above positive effects, GABAergic drugs may further improve the situation by correcting neuroendocrine mechanisms produced by negative memories. In line with this, the amnestic action of GABA-positive modulators has been shown to block conditioned vasopressin, oxytocin, and ACTH stress responses [Carrasco and Van de Kar, 2003]. The latter may lead to the additional (third) useful therapeutic effect of GABAergic-positive modulators targeting the disorders within a complex treatment approach we are presenting here.

The critical role of neuropeptides in modulation of GABAergic function and anxiety/depression interplay also has to be considered. For example, melatonin, which is known to modulate the GABAergic system, was shown to have both anxiolytic and AD properties in animals [Raghavendra et al., 2000]. Similar properties have been found for antagonists of cholecystokinin—the neuropeptide that modulates the GABAergic system and is suggested to be involved in both anxiety and depression pathogenesis [see Lofberg et al., 1998, for details]. Finally, the interaction of GABA with other brain neurotransmitter systems shall be mentioned. For example, the potential for norepinephrine (NE) interaction with GABA in the limbic region [recently suggested by Herman et al., 2003] may be critical since both mediators are largely involved in anxiety and depression pathogenesis [Coplan and Lydiard, 1998]. As such, multiple vs. specific neurotransmitter system dysfunctions shall be considered for possible therapeutic purposes. Perhaps improving anxiety by GABAergic drugs we may at the same time improve depression through the interaction of GABA with NE, and vice versa.

BRAIN CIRCUITS OF ANXIETY AND DEPRESSION

The GABAergic system is now rapidly emerging as a target for development of medications of anxiety and mood disorders [Krystal et al., 2002; Nutt et al., 2002]. It therefore seems important to consider the possible neural anatomical underpinnings of both anxiety and depression relating to GABA [Davidson et al., 2002; Chang et al., 2003]. Chronic stress exposure— the most common cause of depression—has been shown to activate GABAergic forebrain areas, including dorsomedial hypothalamus and hippocampus [Herman et al., 2003]—important parts of depression circuits. Several studies have found significant reductions in hippocampal volume in depressed subjects [see review in Sheline, 2003], indicating the role the hippocampus may play in depression pathogenesis (see Table 6 for details). The hippocampus is particularly rich in GABAergic neurons [Banks et al., 2000]. The well-known role the hippocampus plays in memory, and the role memory plays in anxiety and depression, may link depression and anxiety pathogenesis to memory-related GABAergic processes in the hippocampus.

Brain morphological and metabolic changes associated with major depression have been found in the amygdala [Drevets, 1999; Sheline, 2003]—the GABAergic structure that has long been associated with anxiety and also involved in storage of aversive memories [Davis and Whalen, 2001; Chhatwal et al., 2005]. Proving this putative amygdala–anxiety– depression–memory link, Jasnow and Huhman [2001] reported GABAergic involvement in a conditioned social defeat model in hamsters. In line with these preclinical findings, recent functional MRI studies established marked amygdala activation in response to fearful facial affect in depressed patients vs. normal controls [Yurgelun-Todd et al., 2000]. Interestingly, Strakowski et al. [2002] found that amygdalar changes are specific to the type of depression—with amygdalar volume increased in bipolar disorders and decreased in unipolar depression. The latter raises the possibility that the amygdala plays different roles in various depression disorders and might explain why the drugs affecting GABAergic neurons would differently treat unipolar and bipolar depression.

Recently, the important role of the midbrain tectum was suggested for anxiety and depression pathogenesis [Graeff et al., 1993; Brandao et al., 2003]. The midbrain tectum is rich in GABAergic neurons [Pandossio et al., 2000; Bueno et al., 2005a] and a number of animal studies have shown GABAergic drugs affect the midbrain tectum and alter stress-related anxiety-like behavioral responses, while certain neurochemical or morphological alterations in this brain area have been found in animal depression-like states (Table 6). As such, although clinical studies are still needed to confirm this notion, it seems possible

TABLE 6. Clinical and preclinical data linking common GABAergic brain areas to pathogenesis of anxiety and depression

Anxiety	Depression

Clinical data

Amygdala[a]

Activation in patients with posttraumatic stress disorder [Rauch et al., 1996], during anticipatory anxiety [Phelps et al., 2001], in adults and adolescents viewing fearful faces; also positive correlation of amygdalar activation and social anxiety scores [Morris et al., 1998; Killgore and Yurgelun-Todd, 2005].

Reduced volume in depressed patients [Caetano et al., 2004] and children [Rosso et al., 2005]. Correlation of amygdalar activation in response to emotional faces with symptom improvement in major depression [Canli et al., 2005]. Activation in adults viewing sad vs. happy faces [Killgore and Yurgelun-Todd, 2005].

Hippocampus

Reduced blood flow in anxious volunteers during phobogenic (vs. neutral) visual stimulation [Wik et al., 1993]. Decreased blood flow in right hippocampus in women with post-traumatic stress disorder [Bremner et al., 1999].

Reduced volumes in depressed (including drug-free) patients; negative correlation between hippocampal volumes and length of depression [Caetano et al., 2004; Hickie et al., 2005; Neumeister et al., 2005; Saylam et al., 2006], also see [Sheline et al., 2002] for a detailed review.

Hypothalamus

Activation in patients with panic disorder [Boshuisen et al., 2002].

Activation in depressed patients viewing negative vs. reference images [Malhi et al., 2004].

Prefrontal cortex

Reduced blood flow in anxious volunteers during phobogenic (vs. neutral) visual stimulation [Wik et al., 1993]. Reduced blood flow in women with posttraumatic stress disorder [Bremner et al., 1999].

Altered magnetoencephalographic activity in depressed patients vs. healthy controls [Mainhofner et al., 2005]. Altered metabolism in depressed patients, its correction after electroconvulsive therapy [Michael et al., 2003]. AD effects of repetitive transcranial magnetic stimulation in drug-resistant depressed patients [Rossini et al., 2005].

Midbrain tectum

Activation in patients with panic disorder [Boshuisen et al., 2002]. Panic-like effects following stimulation in humans [Nashold et al., 1969; Amano et al., 1978].

Preclinical data

Amygdala

Reduced anxiety in rats following muscimol injection to basolateral amygdala [Bueno et al., 2005b]. Reduced amygdalar expression of GABA-A receptor associated protein[b] 6 h after fear conditioning in rats [Mei et al., 2005]. Increased c-fos expression[c] in rats following administration of several anxiogenic drugs [Singewald et al., 2003]. Increased lactate-evoked anxiety by bicuculline injected into basolateral amygdala in rats [Sajdyk and Shekhar, 2005]. Correlation between anxiety phenotype in several inbred mouse strains and reduced GABA-A receptor densities, benzodiazepine binding and γ 2 subunit mRNA levels in central, lateral and medial amygdalar nuclei [Yilmazer-Hanke et al., 2003; Caldji et al., 2004]. Reduced extracellular GABA in amygdala in mice exposed to conditioned fear stimulus [Stork et al., 2002].

ADs reduce muricide and amygdaloid after-discharge in rats induced by amygdalar stimulation [Kamei et al., 1975]. Reduced benzodiazepine binding in amygdala 24 h after FST in mice [Briones-Aranda et al., 2005]. Reduced allopregnanolone levels in amygdala in the olfactobulbectomy model of depression in rats [Uzunova et al., 2003]. Altered neurotransmitter turnover in amygdala following FST in Wistar–Kyoto vs. non-stressed or Wistar rats [De La Garza and Mahoney, 2004]. Reduced allopregnanolone levels in amygdala of depressed olfactobulbectomized rats [Uzunova et al., 2003].

Hippocampus

Reduced expression of α 2 GABA-A receptor subunit 6 h after fear conditioning in rats [Mei et al., 2005]. Reduced hippocampal expression of α 1 and α 2 subunits mRNA in punished rats [Zhang et al., 1998]. Altered volume in anxious HAB (vs. low-anxiety LAB) rats [Kalisch et al., 2005]. Increased c-fos expression[c] in rats following administration of several classical anxiogenic drugs [Singewald et al., 2003]. Reduced hippocampal allopregnanolone levels in anxious high-vocalizing rats [Zimmerberg et al., 2005].

Reduced GABA levels 24 h after FST in mice [Briones-Aranda et al., 2005]. Altered cDNA gene expression profile in rats after chronic ADs [Drigues et al., 2003]. Altered hippocampal neurotransmission after FST in rats [Linthorst et al., 2002]. Altered volume in rats with higher depressiveness in FST [Kalisch et al., 2005]. Reduced benzodiazepine binding and GABA-A α 1 subunit mRNA in mice and rats exposed to repeated FST [Medina et al., 1983; Weizman et al., 1989; Montpied et al., 1993].

Hypothalamus

Increased sensitivity to chemically evoked anxiety in rats with experimentally reduced GABA synthesis in hypothalamus [Shekhar et al., 1996]. Increased c-fos expression[c] in rats following administration of several anxiogenic drugs [Singewald et al., 2003]. Reduced anxiety in rats following intra-

Reduced benzodiazepine binding in mice exposed to repeated FST [Weizman et al., 1989]. Reduced GABA levels and benzodiazepine binding 24 h after FST in mice [Briones-Aranda et al., 2005]. Reduced GABAergic transmission and altered GABA-A α 5, γ 1[d] and δ subunits gene expression following

TABLE 6. Continued

Anxiety	Depression
hypothalamic administration of GABAergic anxiolytic drugs [Jardim and Guimaraes, 2001].	3-week chronic unpredictable stress in rats [Verkuyl et al., 2004].
Prefrontal cortex	
Increased c-fos expression[c] in rat prelimbic cortex following administration of several anxiogenic drugs [Singewald et al., 2003]. Reduced anxiety in rats following muscimol infusion into prefrontal cortex [Shah et al., 2004]. Increased anxiety and reduced activity in anxious HAB vs. non-anxious LAB rat strains [Kalisch et al., 2004].	Altered neurotransmitter turnover following FST in Wistar–Kyoto vs. non-stressed or Wistar rats [De La Garza and Mahoney, 2004].
Midbrain tectum	
Panic-like escape behavior in rats evoked by electrical stimulation or microinjections of GABA-A antagonists [Schenberg and Graeff, 1978; Graeff et al., 1986; Brandao et al., 2003], and reduced by GABA-A agonists and benzodiazepines [Bovier et al., 1982; Audi and Graeff, 1984, 1987; Graeff et al., 1986]. Reduced panic-like behavior in rats by intra-DPAG injection of muscimol and baclofen, and increased panic by benzodiazepine inverse agonist FG 7142 [Bueno et al., 2005a]. Increased anxiety by prior electrical stimulation of the inferior colliculus in rats [Pandossio et al., 2000]. Reduced vocalization and freezing in rats following muscimol or midazolam injection into the inferior colliculus [Nobre and Brandao, 2004].	Reduced benzodiazepine binding in mice exposed to repeated FST [Weizman et al., 1989]. Neurochemical changes in mouse inferior colliculus following AD treatment [Williams et al., 2005]. Reduced blood flow in inferior colliculus in several different models of depression in rats [Caldecott-Hazard et al., 1988]. Pronounced neuromorphological changes in inferior colliculus in rats following chronic immobilization stress [Dagnino-Subiabre et al., 2005].

DPAG, dorsal periaqueductal gray; FST, forced swim test of depression; AD, antidepressant.
[a]Also see Quirk and Gehlert [2003] for a detailed review.
[b]Modulates channel kinetics and neurotransmission by promoting GABA-A receptor clustering.
[c]Genetic marker of neuronal activation.
[d]Robust trend ($P = .06$) for this subunit.

that GABAergic influences on the midbrain tectum may play a role in anxiety and depression.

The prefrontal cortex has been reported to be activated by a provocation test across several anxiety disorders [Davidson, 2002; Nestler et al., 2002] and is also an important part of the brain depression circuits (Fig. 1) [Sheline, 2003]. Morphological and metabolic changes associated with depression have been found in the prefrontal cortex in many studies [Yurgelun-Todd et al., 2000; Sheline, 2003]. It is worth mentioning that GABAergic neurons represent the highest population in the cortex and play a crucial role in regulation of inputs and outputs of the cortex. The prefrontal cortex has also been traditionally linked to memory and higher cognitive functions—ones that that are extremely relevant to linking anxiety and depression (see, for example, data on reduced benzodiazepine binding in prefrontal cortex in combat-related posttraumatic stress disorder [Bremner et al., 2000b]). Recent postmortem studies have established that depressive disorders are characterized by alterations in the density and size of neuronal and glial cells in frontolimbic brain regions [Rajkowska, 2003]. Importantly, these regions, rich in GABAergic neurons, are also reported to be involved in anxiety spectrum disorders [Mindus et al., 1986; Wu et al., 1991]. For example, infusion of the GABA agonist muscimol in prefrontal cortex produced clear anxiolytic effects in rats [Shah et al., 2005]. Taken together, the available neuroanatomical

data indicate clear overlapping of several GABAergic neural circuits (Table 6) that may be considered as one integral anxiety/depression circuit (Fig. 1) consisting of three interplaying domains—anxiety, memory, and depression.

GABA NEUROIMAGING DATA

Recent sophisticated neuroimaging methods, such as positron emission (PET) and single photon emission computed (SPECT) tomography and proton magnetic resonance spectroscopy (MRS), enable further neurobiological underpinning of anxiety and depression [Kaschka et al., 1995; Bremner et al., 1997; Malizia et al., 1998; Ketter and Wang, 2002; Chang et al., 2003; Epperson et al., 2005]. Despite certain limitations in spatial and temporal resolution, these methods enable an in vivo real-time assessment of specific areas in these disorders with direct measurement of GABA neurochemistry and comparison of therapeutic effects of different therapies [Bremner et al., 2000a,b; Grachev and Apkarian, 2000; Kosel et al., 2004; Sanacora et al., 2006].

Obtained using different techniques, neuroimaging data firmly confirm the involvement of central GABA in anxiety and depression. In patients with panic disorder, a reduction in benzodiazepine binding in the brain was found by PET [Malizia et al., 1998] and SPECT [Kaschka et al., 1995; Bremner et al., 2000a].

While a similar phenomenon has been revealed by SPECT in patients with posttraumatic stress disorder [Bremner et al., 2000b] or severe treatment-resistant anxiety and depression [Kosel et al., 2004], numerous neuroimaging studies [MRS: Kugaya et al., 2003; Epperson et al., 2006; Sanacora et al., 2006; SPECT: Kosel et al., 2004; Mervaala et al., 2001] consistently show reduced central GABAergic function in depression and its correction by AD therapy (see Tables 2, 3 for details). Strikingly paralleling other clinical and experimental data (reviewed above), these findings further support the notion that impaired GABAergic function is directly involved in anxiety, depression, and their interplay.

CONCLUSION

Summarizing, it seems likely that there are overlapping GABAergic mechanisms of anxiety and depression due to: 1) common neurochemical mechanisms; 2) similar brain structures involved in the regulation of anxiety and depression; 3) common genetic origins of anxiety and depression; and 4) overlapping or correlation in neuropsychopharmacological effects of drugs (Tables 1–6). Consistent overlapping of clinical efficacy as well as activity in animal tests across all classes of GABAergic anxiolytics and antidepressants further strengthens the idea that such effects are not the result of a "lack of specificity," but rather represent a fundamental anxiolytico-antidepressant potential of GABA-A-positive modulators. It is also clear that since GABA, as a part of both anxiety and depression pathogenesis, is responsible for many symptoms of these disorders, drugs that affect GABA-A receptors may be especially useful in selective treatment of symptoms that are common for anxiety and depression (Fig. 2). Here we will make a further step and outline several possible directions for future progress in this field.

1. Since anxiety and depression have many common emotionality features, it may be suggested that GABA-active agents are particularly effective in treating the "emotional" component of both anxiety and depression. The frontolimbic network and especially prefrontal cortex is a key substrate for voluntary suppression of sadness, while chronic incapacity to suppress negative emotions was suggested to be a key factor in the genesis of depression and anxiety [Levesque et al., 2003]. Because GABAergic drugs have been shown to act on this brain structure, it is possible to expect that they may lead to antianxiety and antidepressant effects by improving the patient's ability to control her/his own negative emotions.

2. These drugs may be used as a specific medication of choice for anxiety (and, perhaps, panic) and depression comorbidity states.

3. The fine-tuning and homeostatic balance of the GABAergic inhibitory tone in the brain is a prerequisite for controlling excitatory neurotransmission [Sarup et al., 2003]. Several drugs that affect GABA transport and metabolism also possess effects on anxiety and depression. Further studies on modulation of GABA transport and metabolism are of therapeutical interest in GABA-related disorders, including anxiety and depression.

4. GABAergic drugs may be effective in psychopathologies with mixed or unclear symptoms, and also in some urgent clinical cases of severe anxiety and/or depression. It is especially critical in situations when the previous history of the patient is unknown and/or


Figure 1. Overlapping anxiety and depression circuits (GABAergic areas are in bold).


Figure 2. Multiple targets for GABAergic drugs in a complex treatment of stress-related disorders.

there is no time for proper diagnostics. We therefore speculate that some highly effective potential mood-stabilizing, antipanic, antimanic, and antisuicide drugs may be designed on the basis of selective exogenous or endogenous modulators of the central GABAergic system [see also Shelton, 2003].

5. Since GABA-active neurosteroids play an important role in the pathogenesis of anxiety and depression [Strohle et al., 1999; Guidotti et al., 2001; Reddy, 2003], it is possible to expect that novel GABAergic steroid agents will be a useful tool in the treatment of steroid-dependent disorders including premenstrual and menopausal syndromes [Barbaccia et al., 2000; Sundstrom et al., 1997; Sundstrom-Poromaa et al., 2003] characterized by increased anxiety and depression. In addition, steroids may play a unique modulatory role in tuning sensitivity of GABAergic receptors to GABA and other GABA-active substances [Turner et al., 1989; Olsen et al., 1991; also see Olsen and Sapp, 1995, for review]. The genomic mechanism of neurosteroid action may include effects of expression of genes encoding subunits of GABAergic receptors [Gulinello et al., 2001]. As such, alterations in endogenous steroids during anxiety or depression may largely affect brain GABAergic processes [reviewed in Dubrovsky, 2005; Eser et al., 2006a,b]. This, in turn, may lead to i) further acceleration of the existing anxiety or depression pathogenesis and/or ii) provoke new, secondary (e.g., anxiety, comorbidity, etc.) emotional disorders. Importantly, based on the nature of neurosteroid actions on the nervous system [Reddy, 2003], it is possible to expect that steroid-based GABAergic modulators may in fact create the grounds for the fast-acting AD drugs—the need for which has been so widely recognized.

6. GABA-A receptors appear to occupy a central role in mediating the effects of ethanol in the brain [Davies, 2003]. Alcoholism is often associated with low GABAergic function and increased anxiety and depression [Roy et al., 1991; Enoch, 2003]. A GABAergic genetic component is established for human anxiety, depression, and alcoholism [Nutt et al., 2002; Davies, 2003] as well as alcohol-related phenotypes in animals [Boehm et al., 2004]. Given this and the role of GABA-A receptors in ethanol's behavioral actions [Boehm et al., 2004], the involvement of GABAergic genes in a complex interplay between these three disorders may be postulated. In addition, GABA-active neurosteroids play a pivotal role in the actions of ethanol and in depression associated with chronic ethanol consumption [Hirani et al., 2002, 2005]. Therefore, multitarget complex treatment of anxiety/depression complicated with alcohol abuse [Enoch, 2003] by positive modulators of GABA-A receptors may be a promising therapeutic approach to treat these specific conditions.

7. The important role of cognitive factors in both anxiety and depression pathogenesis [Kalueff and Nutt, 1996] outlines further possibilities where GABAergic drugs may theoretically have extraordinary effectiveness. It is well known that several subtypes of anxiety and depression are characterized by recurrent unpleasant cognitions that complicate therapy and, in fact, are a key part of pathogenesis per se (Fig. 2). Since GABAergic drugs are traditionally known to possess robust effects on memory [reviewed in Kalueff and Nutt, 1996; Chapouthier and Venault, 2002], we suggest that their use may be especially effective in targeting anxiety and/or depression associated with negative memories [also see good recent reviews in Quirk and Gehlert, 2003; Barad, 2005]. Importantly, the same approach may be used for a complex treatment of patients with posttraumatic stress disorder. Inhibition of such memories by GABAergic-positive modulators in some cases could be an important part of rational antidepressant and anxiolytic therapy.

8. Stress as well as many GABAergic psychotropic drugs have been reported to change GABA receptor subunits expression, while the composition of GABA receptors is known to dramatically affect its functions [Zhang et al., 1998; Vekovisheva, 2003]. As such, "programming" of GABAergic receptors by stress (including anxiety and depression) may not only facilitate the existing disorder but provoke a new illness or induce comorbidity states. However, modulation of the GABA receptor composition by GABAergic drugs may provide us with an additional therapeutic tool to fight anxiety and depression disorders. For example, while affecting one disorder (e.g., anxiety) through direct anxiolytic action, certain GABAergic drugs may influence type- and region-specific expression of the receptor subunits. The latter may lead to additional therapeutic effects of the drug targeting the second (e.g., depression) disorder due to changes in the GABA receptor properties.

9. Finally, since all currently available medications for mood disorders exert their therapeutic effects in weeks or months, there is a widely recognized need to find novel drugs that will affect depression much faster [Freeman, 1997; Nestler et al., 2002]. GABAergic drugs, acting both pharmacologically and genomically, might represent a particularly promising area of research in this field. Indeed, upregulation of GABA-A receptor subunits expression by benzodiazepines occurred within several days vs. several weeks needed for similar effects produced by traditional antidepressants [Tanay et al., 2001].

Together, it is now clear that, accompanied by intensive studies in the field of pharmacological and neurogenetical regulation of memory, anxiety, and depression, the "anxiety-depression" GABAergic concept that we develop here may significantly improve our understanding of the general mechanisms underlying stress-induced brain disorders. It may also point to new directions for a rational search for novel agents and even classes of stress-protecting psychotropic drugs.

REFERENCES

Aley KO, Kulkarni SK. 1989. GABA-mediated modification of despair behavior in mice. Naunyn Schmied Arch Pharmacol 339:306–311.

Altshuler LL, Keck PE Jr, McElroy SL, Suppes T, Brown ES, Denicoff K, Frye M, Gitlin M, Hwang S, Goodman R, Leverich G, Nolen W, Kupka R, Post R. 1999. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disord 1:61–65.

Amano K, Tanikama T, Iseki H, Kawabatake H, Notani M, Kawamura H. 1978. Single neuron analysis of the midbrain tegmentum: rostral mesencephalic reticulotomy of pain relief. Appl Neurophysiol 41:66–78.

Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. 1999. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 160:1–12.

Argyropoulos SV, Nutt DJ. 1997. Anhedonia and chronic mild stress model in depression. Psychopharmacology 134:333–336.

Argyropoulos SV, Nutt DJ. 1999. The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 9(Suppl 6):S407–S412.

Argyropoulos SV, Sandford JJ, Nutt DJ. 2000. The psychobiology of anxiolytic drug. 2. Pharmacological treatments of anxiety. Pharmacol Ther 88:213–227.

Atack JR. 2003. Anxioselective compounds acting at the GABAa receptor benzodiazepine binding site. Curr Drug Targ CNS Neurol Disord 2:213–232.

Atack JR. 2005. The benzodiazepine binding site of GABA-A receptors as a target for the development of novel anxiolytics. Expert Opin Investig Drugs 14:599–616.

Atack JR, Hutson PH, Collinson N, Marcshall G, Bentley G, Moyes C, Cook SM, Collins I, Wafford K, McKerman RM, Dawson GR. 2005. Anxiogenic properties of an inverse agonist selective for α3 subunit-containing GABAA receptors. Br J Pharmacol 144:357–366.

Audi EA, Graeff FG. 1984. Benzodiazepine receptors in the periaqueductal grey mediate anti-aversive drug action. Eur J Pharmacol 103:279–285.

Audi EA, Graeff FG. 1987. GABAA receptors in the midbrain central grey mediate the antiaversive action of GABA. Eur J Pharmacol 135:225–229.

Bai F, Li M, Clay M, Lindstrom T, Skolnick P. 2001. Intra- and inter-strain differences in models of "behavioral despair.". Pharmacol Biochem Behav 70:187–192.

Banks MI, White JA, Pearce RA. 2000. Interactions between distinct GABA(A) circuits in hippocampus. Neuron 25:449–457.

Barad M. 2005. Fear extinction in rodents: basic insight to clinical promise. Curr Opin Neurobiol 15:710–715.

Barbaccia ML, Costa E, Ferrero P, Guidotti A, Roy A, Sunderland T, Pickar D, Paul SM, Goodwin FK. 1986. Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. Arch Gen Psychiatry 43:1143–1147.

Barbaccia ML, Lello S, Sidiropoulou T, Cocco T, Sorge RP, Cocchiarale A, Piermarini V, Sabato AF, Trabucchi M, Romanini C. 2000. Plasma 5alpha-androstane-3alpha,17betadiol, an endogenous steroid that positively modulates GABA(A) receptor function, and anxiety: a study in menopausal women. Psychoneuroendocrinology 25:659–675.

Bartholini G. 1984. Experimental basis for the antidepressant action of the GABA receptor agonist progabide. Neurosci Lett 47:351–355.

Battaglia M, Ogliari A. 2005. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 29:169–179.

Beijamini V, Skalisz LL, Joca SR, Andreatini R. 1998. The effect of oxcarbazepine on behavioral despair and learned helplessness. Eur J Pharmacol 347:23–27.

Belelli D, Lambert JJ. 2005. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6:565–575.

Bell MV, Bloomfield J, McKinley M, Patterson MN, Darlison MG, Barnard EA, Davies KE. 1989. Physical linkage of a GABAA receptor subunit gene to the DXS374 locus in human Xq28. Am J Hum Genet 45:883–888.

Belozertseva IV, Andreev BV. 1997. A pharmaco-ethological study of the GABA-ergic mechanisms regulating the depression-like behavior of mice. Zh VND Im I P Pavlova 47:1024–1031.

Belzung C. 2001. Rodent models of anxiety-like behaviors: are they predictive for compounds acting via non-benzodiazepine mechanisms? Curr Opin Investig Drugs 2:1108–1111.

Besag FM. 2001. Behavioral effects of the new anticonvulsants. Drug Saf 24:513–536.

Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. 2004. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. Am J Psychiatry 161:368–370.

Birkenhager TK, Moleman P, Nolen WA. 1995. Benzodiazepines for depression? A review of the literature. Int Clin Psychopharmacol 10:181–195.

Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ, Petty F. 2001. Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101:131–136.

Boehm SL, Ponomarev I, Jennings AW, Whitting PJ, Rosahl TW, Garrett EM, Blednov YA, Harris A. 2004. γ-Aminobutyric acid A receptor subunit mutant mice: new perspectives on alcohol actions. Biochem Pharmacol 68:1581–1602.

Borsini F, Evangelista S, Meli A. 1986. Effect of GABAergic drugs in the behavioral 'despair' test in rats. Eur J Pharmacol 121:265–268.

Borsini F, Mancinelli A, D'Aranno V, Evangelista S, Meli A. 1988. On the role of endogenous GABA in the forced swimming test in rats. Pharmacol Biochem Behav 29:275–279.

Borsini F, Podhorna J, Marazziti D. 2002. Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology 163:121–141.

Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. 2002. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52:126–135.

Bourin M, Colombel MC, Malinge M, Bradwejn J. 1991. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci 16:199–203.

Bovier P, Broekkamp CL, Lloyd KG. 1982. Enhancing GABAergic transmission reverses the aversive state in rats induced by electrical stimulation of the periaqueductal grey region. Brain Res 248:313–320.

Brambilla P, Perez J, Barale F, Schettini G, Soares JC. 2003. GABAergic dysfunction in mood disorders. Mol Psychiatry 8:721–737, 715.

Brandao ML, Troncoso AC, de Souza Silva MA, Huston JP. 2003. The relevance of neuronal substrates of defense in the midbrain tectum to anxiety and stress: empirical and conceptual considerations. Eur J Pharmacol 463:225–233.

Bremner JD, Innis RB, Salomon RM, Staib LH, Ng CK, Miller HL, Bronen RA, Krystal JH, Duncan J, Rich D, Price LH, Malison R, Dey H, Soufer R, Charney DS. 1997. Positron emission

tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse. Arch Gen Psychiatry 54:364–374.

Bremner JD, Narayan M, Staib LH, Southwick SM, McGlashan T, Charney DS. 1999. Neural correlates of memories of childhood sexual abuse in women with and without posttraumatic stress disorder. Am J Psychiatry 156:1787–1795.

Bremner JD, Innis RB, White T, Fujita M, Silbersweig D, Goddard AW, Staib L, Stern E, Cappiello A, Woods S, Baldwin R, Charney DS. 2000a. SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol Psychiatry 47:96–106.

Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. 2000b. Decreased benzodiazepine receptor binding in prefrontal cortex in combat-related posttraumatic stress disorder. Am J Psychiatry 157:1120–1126.

Briones-Aranda A, Rocha L, Picazo O. 2005. Alterations in GABAergic function following forced swimming stress. Pharmacol Biochem Behav 80:463–470.

Buckle VJ, Fujita N, Ryder-Cook AS, Derry JM, Barnard PJ, Lebo RV, Schofield PR, Seeburg PH, Bateson AN, Darlison MG. 1989. Chromosomal localization of GABAA receptor subunit genes: relationship to human genetic disease. Neuron 3:647–654.

Bueno CH, Zangrossi H Jr, Nogueira RL, Soares VP, Viana MB. 2005a. Panicolytic-like effect induced by the stimulation of GABAA and GABAB receptors in the dorsal periaqueductal grey of rats. Behav Brain Res 21:65–72.

Bueno CH, Zangrossi H Jr, Viana MB. 2005b. The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated T-maze and light/dark transition tests. Braz J Med Biol Res 38:1697–1701.

Bullock AE, Clark AL, Grady SR, Robinson SF, Slobe BS, Marks MJ, Collins AC. 1997. Neurosteroids modulate nicotinic receptor function in mouse striatal and thalamic synaptosomes. J Neurochem 68:2412–2423.

Caetano SC, Hatch JP, Brambilla P, Sassi RB, Nicoletti M, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC. 2005. Anatomical MRI study of hippocampus and amygdala in patients with current and remitted major depression. Psychiatry Res 132:141–147.

Caldecott-Hazard S, Mazziotta J, Phelps M. 1988. Cerebral correlates of depressed behavior in rats, visualized using 14C-2-deoxyglucose autoradiography. J Neurosci 8:1951–1961.

Caldji C, Diorio J, Anisman H, Meaney MJ. 2004. Maternal behavior regulates benzodiazepine/GABAA receptor subunit expression in brain regions associated with fear in BALB/c and C57BL/6 mice. Neuropsychopharmacology 29:1344–1352.

Canli T, Cooney RE, Goldin P, Shah M, Sivers H, Thomason ME, Whitfield-Gabrieli S, Gabrieli JD, Gotlib IH. 2005. Amygdala reactivity to emotional faces predicts improvement in major depression. Neuroreport 16:1267–1270.

Cannizzaro G, Flugy A, Cannizzaro C, Gagliano M, Sabatino M. 1993. Effects of desipramine and alprazolam in the forced swim test in rats after long-lasting termination of chronic exposure to picrotoxin and pentylenetetrazol. Eur Neuropsychopharmacol 3:477–484.

Carobrez AP, Bertoglio LJ. 2005. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 29:1193–1205.

Carrasco GA, Van de Kar LD. 2003. Neuroendocrine pharmacology of stress. Eur J Pharmacol 463:235–272.

Chandra D, Korpi ER, Miralles CP, De Blas AL, Homanics GE. 2005. GABAA receptor γ2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci 6:30.

Chang L, Cloak CC, Ernst T. 2003. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders. J Clin Psychiatry 64(Suppl 3):7–14.

Chapouthier G, Venault P. 2002. GABA-A receptor complex and memory processes. Curr Top Med Chem 2:841–851.

Chhatwal JP, Myers KM, Ressler KJ, Davis M. 2005. Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 25:502–506.

Chopra K, Kunchandy J, Kulkarni SK. 1988. Benzodiazepine inverse agonist FG-7142-induced delayed behavioral depression in mice. Arch Int Pharmacodyn Ther 294:56–63.

Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE, Akil H, Watson SJ, Jones EG. 2005. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102:15653–15658.

Clement Y, Chapouthier G. 1998. Biological bases of anxiety. Neurosci Biobehav Rev 22:623–633.

Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, Smith A, Out FM, Howell O, Atack JR, McKernan RM, Seabrook GR, Dawson GR, Whiting PJ, Rosahl TW. 2002. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the α5 subunit of the GABAA receptor. J Neurosci 22:5572–5580.

Connor KM, Davidson JRT, Weisler RH, Zhang W, Abraham K. 2006. Tiagabin for post-traumatic stress disorder: effect of open-label and double-blind discontinuation treatment. Psychopharmacology 184:21–25.

Coplan JD, Lydiard RB. 1998. Brain circuits in panic disorder. Biol Psychiatry 44:1264–1276.

Crane D. 2003. Tiagabine for the treatment of anxiety. Depress Anxiety 18:51–52.

Crawley JN. 1999. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835:18–26.

Crawley JN. 2000. What's wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. New York: Wiley-Liss.

Crestani F, Lorez M, Baer K, Essrich C, Benke D, Laurent JP, Belzung C, Fritschy JM, Luscher B, Mohler H. 1999. Decreased GABA-A receptor clustering results in enhanced anxiety and bias for threat cues. Nat Neurosci 2:833–839.

Crowley JJ, Lucki I. 2005. Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Curr Pharm Design 11:157–169.

Crunelli V, Emri Z, Leresche N. 2006. Unravelling the brain targets of gamma-hydroxybutyric acid. Curr Opin Pharmacol 6:1–9.

Cryan JF, Holmes A. 2005. The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4:775–790.

Cryan JF, Kaupmann K. 2005. Don't worry "B" happy: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 26:36–43.

Cryan JF, Mombereau C. 2004. In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatry 9:326–357.

Cryan JF, Markou A, Lucki I. 2002. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238–245.

Cryan JF, Valentino RJ, Lucki I. 2005. Assessing substrates underlying the behavioral effects of antidepressants using the

modified rat forced swimming test. Neurosci Biobehav Rev 29: 547–569.

Dagnino-Subiabre A, Terreros G, Carmona-Fontaine C, Zepeda R, Orellana JA, Diaz-Veliz G, Mora S, Aboitiz F. 2005. Chronic stress impairs acoustic conditioning more than visual conditioning in rats: morphological and behavioral evidence. Neuroscience 135: 1067–1074.

Dalvi A, Rodgers RJ. 1996. GABAergic influences on plus-maze behavior in mice. Psychopharmacology 128:380–397.

Daly RC, Schmidt PJ, Davis CL, Danaceau MA, Rubinow DR. 2001. Effects of gonadal steroids on peripheral benzodiazepine receptor density in women with PMS and controls. Psychoneuroendocrinology 26:539–549.

Davidson RJ. 2002. Anxiety and affective style: role of prefrontal cortex and amygdala. Biol Psychiatry 51:68–80.

Davidson RJ, Lewis DA, Alloy LB, Amaral DG, Bush G, Cohen JD, Drevets WC, Farah MJ, Kagan J, McClelland JL, Nolen-Hoeksema S, Peterson BS. 2002. Neural and behavioral substrates of mood and mood regulation. Biol Psychiatry 52:478–502.

Davies M. 2003. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci 28:263–274.

Davis M, Whalen PJ. 2001. The amygdala: vigilance and emotion. Mol Psychiatry 6:13–34.

De La Garza, Mahoney JJ. 2004. A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. Brain Res 1021: 209–218.

Dennis T, Beauchemin V, Lavoie N. 1994. Antidepressant-induced modulation of GABAA receptors and beta-adrenoceptors but not GABAB receptors in the frontal cortex of olfactory bulbectomised rats. Eur J Pharmacol 262:143–148.

Dong E, Matsumoto K, Tohda M, Kaneko Y, Watanabe H. 1999. Diazepam binding inhibitor (DBI) gene expression in the brains of socially isolated and group-housed mice. Neurosci Res 33: 171–177.

Do-Rego JC, Suaudeau C, Chapouthier G, Costentin J. 2002. Mouse lines differing in sensitivity to beta-CCM differ in tasks used for testing antidepressants. Pharmacol Biochem Behav 72:411–416.

Drake RG, Davis LL, Cates ME, Jewell ME, Ambrose SM, Lowe JS. 2003. Baclofen treatment for chronic posttraumatic stress disorder. Ann Pharmacother 37:1177–1181.

Drevets WC. 1999. Prefrontal cortical-amygdalar metabolism in major depression. Ann N Y Acad Sci 877:614–637.

Drigues N, Poltyrev T, Bejar C, Weinstock M, Youdim MB. 2003. cDNA gene expression profile of rat hippocampus after chronic treatment with antidepressant drugs. J Neural Transm 110: 1413–1436.

Drugan RC, Maier SF, Skolnick P, Paul SM, Crawley JN. 1985. An anxiogenic benzodiazepine receptor ligand induces learned helplessness. Eur J Pharmacol 113:453–457.

Drugan RC, Morrow AL, Weizman R, Weizman A, Deutsch SI, Crawley JN, Paul SM. 1989. Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 487:45–51.

Drugan RC, Paul SM, Crawley JN. 1993. Decreased forebrain [35S]TBPS binding and increased [3H]muscimol binding in rats that do not develop stress-induced behavioral depression. Brain Res 631:270–276.

Dubrovsky BO. 2005. Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 29:169–192.

Edenberg HJ, Foroud T, Conneally PM, Sorbel JJ, Carr K, Crose C, Willig C, Zhao J, Miller M, Bowman E, Mayeda A, Rau NL, Smiley C, Rice JP, Goate A, Reich T, Stine OC, McMahon F, DePaulo JR, Meyers D, Detera-Wadleigh SD, Goldin LR, Gershon ES, Blehar MC, Nurnberger JI. 1997. Initial genomic scan of the NIMH genetics initiative bipolar pedigree: chromosomes 3, 5, 15, 16, 17, and 22. Am J Med Genet 74:238–246.

Emrich HM, von Zerssen D, Kissling W, Moller HJ, Windorfer A. 1980. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 229:1–16.

Enoch MA. 2003. Pharmacogenomics of alcohol response and addiction. Am J Pharmacogenomics 3:217–232.

Epperson CN, Gueorguieva R, Czarkowski KA, Stiklus S, Sellers E, Krystal JH, Rothman DL, Mason GF. 2006. Preliminary evidence of reduced occipital GABA concentrations in puerperal women: a 1H-MRS study. Psychopharmacology 186:425–433.

Erickson K, Drevets W, Schulkin J. 2003. Glucocorticoid regulation of diverse cognitive functions in normal and pathological emotional states. Neurosci Biobehav Rev 27:233–246.

Eser D, Schule C, Romeo E, Baghai TC, di Michele F, Pasini A, Zwanzger P, Padberg F, Rupprecht R. 2006a. Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders. Psychopharmacology 186:373–387.

Eser D, Romeo E, Baghai TC, di Michele F, Schule C, Pasini A, Zwanzger P, Padberg F, Rupprecht R. 2006b. Neuroactive steroids as modulators of depression and anxiety. Neuroscience 138: 1041–1048.

Estrada-Camarena E, Contreras CM, Saavedra M, Luna-Baltazar I, Lopez-Rubalcava C. 2002. Participation of the lateral septal nuclei (LSN) in the antidepressant-like actions of progesterone in the forced swimming test (FST). Behav Brain Res 134:175–183.

Fatemi SH, Stary JM, Earle JA, Araghi-Nikham M, Eagan E. 2005. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 and Reelin proteins in cerebellum. Schizophr Res 72:109–122.

Fernandez Teruel A, Boix F, Escorihuela RM, Yanez P, Tobena A. 1988. Sodium valproate reduces immobility in the behavioral 'despair' test in rats. Eur J Pharmacol 152:1–7.

Feusner J, Ritchie T, Lawford B, Young RM, Kann B, Nobre EP. 2001. GABAA receptor β3 subunit gene and psychiatric morbidity in a post-traumatic stress disorder population. Psychiatry Res 104: 109–117.

File SE, Mabbutt PS, Andrews N. 1991. Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology 104:62–66.

File SE, Zharkovsky A, Hitchcott PK. 1992. Effects of nitrendipine, chlordiazepoxide, flumazenil and baclofen on the increased anxiety resulting from alcohol withdrawal. Prog Neuropsychopharmacol Biol Psychiatry 16:87–93.

Finn DA, Rutledge-Gorman MT, Crabbe JC. 2003. Genetic animal models of anxiety. Neurogenetics 4:109–135.

Flint J. 2002. Genetic effects on an animal model of anxiety. FEBS Lett 529:131–134.

Flint J. 2003. Animal models of anxiety and their molecular dissection. Semin Cell Dev Biol 14:37–42.

Flugy A, Gagliano M, Cannizzaro C, Novara V, Cannizzaro G. 1992. Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. Eur J Pharmacol 214: 233–238.

Fong GCY, Cheung BMY, Kumana CR. 2003. Gabapentin. Med Prog 2:1–8.

Freeman HL. 1997. Advantages and limitations of the concept of antidepressant therapy. Eur Neuropsychopharmacol 7(Suppl 3): S315–S321.

Freeman MP, Freeman SA, McElroy SL. 2002. The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J Affect Disord 68:1–23.

Gajwani P, Forsthoff A, Muzina D, Amann B, Gao K, Elhaj O, Calabrese JR, Grunze H. 2005. Antiepileptic drugs in mood-disordered patients. Epilepsia 46(Suppl 4):38–44.

George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. 1994. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry 35:775–780.

Geyer MA, Markou A. 1995. Animal models of psychiatric disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press. p 787–798.

Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. 1998. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry 59:426–429.

Gill KJ, Boyle AE. 2005. Quantitative trait loci for novelty/stress-induced locomotor activation in recombinant inbred (RI) and recombinant congenic (RC) strains of mice. Behav Brain Res 161: 113–124.

Gillespie NA, Kirk KM, Evans DM, Heath AC, Hickie IB, Martin NG. 2004. Do the genetic or environmental determinants of anxiety and depression change with age? A longitudinal study of Australian twins. Twin Res 7:39–53.

Gilmer WS. 2001. Anticonvulsants in the treatment of mood disorders: assessing current and future roles. Expert Opin Pharmacother 2:1597–1608.

Goddard AW, Mason GF, Appel M, Rothman DL, Gueorguieva R, Behar KL, Krystal JH. 2004. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry 161:2186–2193.

Gomez R, Vargas CR, Wajner M, Barros HM. 2003. Lower in vivo brain extracellular GABA concentration in diabetic rats during forced swimming. Brain Res 968:281–284.

Grachev ID, Apkarian AV. 2000. Anxiety in healthy humans is associated with orbital frontal chemistry. Mol Psychiatry 5: 482–488.

Graeff FG, Brandao ML, Audi EA, Schutz MT. 1986. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav Brain Res 21:65–72.

Graeff FG, Silveira MC, Nogueira RL, Audi EA, Oliveira RM. 1993. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav Brain Res 58:123–131.

Guidotti A. 1991. Role of DBI in brain and its posttranslational processing products in normal and abnormal behavior. Neuropharmacology 30:1425–1433.

Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR, Impagnatiello F, Pandey G, Pesold C, Sharma R, Uzunov D, Costa E. 2000. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57: 1061–1069.

Guidotti A, Dong E, Matsumoto K, Pinna G, Rasmusson AM, Costa E. 2001. The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5alpha-dihydroprogesterone in psychiatric disorders. Brain Res Rev 37:110–115.

Gulinello M, Gong QH, Li X, Smith SS. 2001. Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat. Brain Res 910:55–66.

Hayase T, Yamamoto Y, Yamamoto K. 2002. Toxic cocaine- and convulsant-induced modification of forced swimming behaviors and their interaction with ethanol: comparison with immobilization stress. BMC Pharmacol 2:19.

Henkel V, Baghai TC, Eser D, Zill P, Mergl R, Zwanzger P, Schulle C, Bottlender R, Jager M, Rupprecht R, Hegerl U, Moller HJ, Bondy B. 2004. The gamma amino butyric acid (GABA) receptor alpha-3 subunit gene polymorphism in unipolar depressive disorder: a genetic association study. Am J Med Genet 126: 82–87.

Herman JP, Renda A, Bodie B. 2003. Norepinephrine-gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. Biol Psychiatry 53:166–174.

Hickie I, Naismith S, Ward PB, Turner K, Scott E, Mitchell P, Wilhelm K, Parker G. 2005. Reduced hippocampal volumes and memory loss in patients with early- and late-onset depression. Br J Psychiatry 186:197–202.

Hilakivi LA, Taira T, Hilakivi I, Loikas P. 1988. Neonatal treatment with monoamine uptake inhibitors alters later response in behavioral 'despair' test to beta and GABA-B receptor agonists. Pharmacol Toxicol 63:57–61.

Hinderer SR. 1990. The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am J Phys Med Rehabil 69:254–258.

Hirani K, Khisti RT, Chopde CT. 2002. Behavioral action of ethanol in Porsolt's forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20-one. Neuropharmacology 43:1339–1350.

Hirani K, Sharma AN, Jain NS, Ugale RR, Chopde CT. 2005. Evaluation of GABAergic neuroactive steroid 3alpha-hydroxy-5alpha-pregnane-20-one as a neurobiological substrate for the anti-anxiety effect of ethanol in rats. Psychopharmacology 180: 267–278.

Hisama FM, Gruen JR, Choi J, Huseinovic M, Grigorenko EL, Pauls D, Mattson RH, Gelernter J, Wood FB, Goei VL. 2001. Human GABAA receptor 1 gene: eight novel sequence variants. Human Mutat 17:349–350.

Ho YJ, Eichendorff J, Schwarting RK. 2002. Individual response profiles of male Wistar rats in animal models for anxiety and depression. Behav Brain Res 136:1–12.

Horiuchi Y, Nakayama J, Ishiguro H, Ohtsuki T, Detera-Wadleigh S, Toyota T, Yamada K, Nankai M, Shibuya H, Yoshikawa T, Arinami T. 2004. Possible association between a haplotype of the GABA-A receptor α1 subunit gene (GABRA1) and mood disorders. Biol Psychiatry 55:40–45.

Jamous A, Kennedy P, Psychol C, Grey N. 1994. Psychological and emotional effects of the use of oral baclofen: a preliminary study. Paraplegia 32:349–353.

Jardim MC, Guimaraes FS. 2001. GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus. Pharmacol Biochem Behav 69:579–584.

Jasnow AM, Huhman KL. 2001. Activation of GABA(A) receptors in the amygdala blocks the acquisition and expression of conditioned defeat in Syrian hamsters. Brain Res 920:142–150.

Joca SR, Skalisz LL, Beijamini V, Vital MA, Andreatini R. 2000. The antidepressive-like effect of oxcarbazepine: possible role of dopaminergic neurotransmission. Eur Neuropsychopharmacol 10: 223–238.

Kalisch R, Salome N, Platzer S, Wigger A, Czisch M, Sommer W, Singewald N, Heilig M, Berthele A, Holsboer F, Landgraf R, Auer DP. 2004. High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. Neuroimage 23:382–391.

Kalisch R, Schubert M, Jacob W, Kessler MS, Hemauer R, Wigger A, Landgraf R, Auer DP. 2005. Anxiety and hippocampus volume in the rat. Neuropsychopharmacology 1–8.

Kalueff AV. 1997. New problems in GABAergic pharmacology of anxiety. Eksp Klin Farmakol 60:3–7.

Kalueff A, Nutt DJ. 1996. Role of GABA in memory and anxiety. Depress Anxiety 4:100–110.

Kamei C, Masuda Y, Oka M, Shimizu M. 1975. Effects of antidepressant drugs on amygdaloid after-discharge in rats. Jpn J Pharmacol 25:359–365.

Kaschka W, Feistel H, Ebert D. 1995. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 29:427–434.

Kash SF, Tecott LH, Hodge C, Baekkeskov S. 1999. Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 96:1698–1703.

Katsura M, Mohri Y, Shuto K, Tsujimura A, Ukai M, Ohkuma S. 2002. Psychological stress, but not physical stress, causes increase in diazepam binding inhibitor (DBI) mRNA expression in mouse brains. Mol Brain Res 104:103–109.

Kaufmann KR. 1998. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 10:181–184.

Kelly JP, Wrynn AS, Leonard BE. 1997. The olfactory bulbecto-mized rat as a model of depression: an update. Pharmacol Ther 74:299–316.

Kendler KS, Heath A, Martin NG, Eaves LJ. 1986. Symptoms of anxiety and depression in a volunteer twin population. The etiologic role of genetic and environmental factors. Arch Gen Psychiatry 43:213–221.

Kendler KS, Heath AC, Martin NG, Eaves LJ. 1987. Symptoms of anxiety and symptoms of depression. Same genes, different environments? Arch Gen Psychiatry 44:451–457.

Keros S, Hablitz JJ. 2005. Subtype-specific GABA trans-porter antagonists synergetically modulate phasic and tonic GABAA conductance in rat neocortex. J Neurophysiol 94:2073–2085.

Ketter TA, Wang PW. 2002. Predictors of treatment response in bipolar disorders: evidence from clinical and brain imaging studies. J Clin Psychiatry 63(Suppl 3):21–25.

Khisti RT, Chopde CT, Jain SP. 2000. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 67:137–143.

Khisti RT, Penland SN, VanDoren MJ, Grobin AC, Morrow AL. 2002. GABAergic neurosteroid modulation of ethanol actions. World J Biol Psychiatry 3:87–95.

Killgore WD, Yurgelun-Todd DA. 2004. Activation of the amygdala and anterior cingulate during nonconscious processing of sad versus happy faces. Neuroimage 21:1215–1223.

Killgore WD, Yurgelun-Todd DA. 2005. Social anxiety predicts amygdala activation in adolescents viewing fearful faces. Neuro-report 16:1671–1675.

Korpi ER, Sinkkonen ST. 2006. GABAa receptor subtypes as targets for neuropsychiatric drug development. Pharmacol Ther 109:12–32.

Korpi ER, Grunder G, Luddens H. 2002. Drug interactions at GABA(A) receptors. Prog Neurobiol 67:113–159.

Kosel M, Rudolph U, Wielepp P, Luginbuhl M, Schmitt W, Fisch HU, Schlaeper TE. 2004. Diminished GABAa receptor-binding capacity and a DNA base substitution in a patient with treatment-resistant depression and anxiety. Neuropsychopharmacology 29:347–350.

Kram ML, Kramer GL, Steciuk M, Ronan PJ, Petty F. 2000. Effects of learned helplessness on brain GABA receptors. Neurosci Res 38:193–198.

Kroes RA, Panksepp J, Burgdorf J, Otto NJ, Moskal JR. 2005. Modeling depression: social dominance-submission gene expres-sion patterns in rat neocortex. Neuroscience 137:37–49.

Krupitskii EM, Burakov AM, Ivanov VB, Karandashova GF, Lapin IP, Grinenko AIa, Borodkin IuS. 1994. The use of baclofen for treating affective disorders in alcoholism. Zh Nevropatol Psikhiatr Korsakov 94:57–61.

Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. 2002. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry 7(Suppl 1):S71–S80.

Kugaya A, Sanacora G, Verhoeff NPLG, Fujita M, Mason GF, Seneca NM, Bozkurt A, Khan SA, Anand A, Degen K, Charney DS, Zoghbi SS, Baldwin RM, Seybil JP, Innis RB. 2003. Cerebral benzodiazepine receptors in depressed patients measured with [^{123}I]iomazenil SPECT. Biol Psychiatry 54:792–799.

Lang AP, de Angelis L. 2003. Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test. Methods Find Exp Clin Pharmacol 25:265–271.

Lapin I. 2001. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev 7:471–481.

Lappalainen J, Sanacora G, Kranzler HR, Malison R, Hibbard ES, Price LH, Krystal J, Gelernter J. 2004. Mutation screen of the glutamate decarboxylase-67 gene and haplotype association to unipolar depression. Am J Med Genet 124:81–86.

Lemoine P, Boulenger JP, Caillard V, Tanne N, Bonnet D. 1991. Compared efficacy of prazepam and clomipramine in major depression with anxiety: a multicenter controlled study. Pharma-copsychiatry 24:175–179.

Leung JW, Xue H. 2003. GABAergic functions and depression: from classical therapies to herbal medicine. Curr Drug Targets CNS Neurol Disord 2:363–374.

Levesque J, Eugene F, Joanette Y, Paquette V, Mensour B, Beaudoin G, Leroux JM, Bourgouin P, Beauregard M. 2003. Neural circuitry underlying voluntary suppression of sadness. Biol Psychiatry 53:502–510.

Linthorst AC, Penalva RG, Flachskamm C, Holsboer F, Reul JM. 2002. Forced swim stress activates rat hippocampal sero-tonergic neurotransmission involving a corticotropin-releasing hormone receptor-dependent mechanism. Eur J Neurosci 16:2441–2452.

Lloyd KG, Morselli PL, Depoortere H, Fournier V, Zivkovic B, Scatton B, Broekkamp C, Worms P, Bartholini G. 1983. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 18:957–966.

Lloyd KG, Thuret F, Pilc A. 1985. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. J Pharmacol Exp Ther 235:191–199.

Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G. 1987. Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. J Pharmacol Exp Ther 241:245–250.

Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G. 1989. The gabaergic hypothesis of depression. Prog Neuropsychophar-macol Biol Psychiatry 13:341–351.

Lofberg C, Agren H, Harro J, Oreland L. 1998. Cholecystokinin in CSF from depressed patients: possible relations to severity of depression and suicidal behavior. Eur Neuropsychopharmacol 8:153–157.

Lopez JF, Akil H, Watson SJ. 1999. Neural circuits mediating stress. Biol Psychiatry 46:1461–1471.

Lundorf MD, Buttenschon HN, Foldagen L, Blackwood DH, Muir WL, Murray V, Pelose AJ, Kruse TA, Ewald H, Mors O. 2005. Mutational screening and association study of glutamate decarboxylase 1 as a candidate susceptibility gene for bipolar disorders and schizophrenia. Am J Med Genet 135:94–101.

Lydiard RB. 2003. The role of GABA in anxiety disorders. J Clin Psychiatry 64(Suppl 3):21–27.

Maihofner C, Ropohl A, Reulbach U, Hiller M, Elstner S, Kornhuber J, Sperling W. 2005. Effects of repetitive transcranial magnetic stimulation in depression: a magnetoencephalographic study. Neuroreport 16:1839–1842.

Malatynska E, De Leon I, Allen D, Yamamura HI. 1995. Effects of amitriptyline on GABA-stimulated 36CI-uptake in relation to a behavioral model of depression. Brain Res Bull 37:53–59.

Malatynska E, Crites GJ, Harrawood D, Goldenberg R, Matheson GK. 2000. Antidepressant effects on GABA-stimulated 36Cl(-) influx in rat cerebral cortex are altered after treatment with GABA(A) receptor antisense oligodeoxynucleotides. Brain Res 869:78–84.

Malhi GS, Lagopoulos J, Ward PB, Kumari V, Mitchell PB, Parker GB, Ivanovski B, Sachdev P. 2004. Cognitive generation of affect in bipolar depression: an fMRI study. Eur J Neurosci 19: 741–754.

Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. 1998. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55:715–720.

Marowsky A, Fritschy JM, Vogl KE. 2004. Functional mapping of GABAA receptor subtypes in the amygdala. Eur J Neurosci 20: 1281–1289.

Martin SC, Russek SJ, Farb DH. 2001. Human GABAbR genomic structure: evidence for splice variants in GABAbR1 but not GABAbR2. Gene 278:63–79.

Massat I, Souery D, Del-Favero J, Oruc L, Noethen MM, Blackwood D, Thomson M, Muir W, Papadimitrious GN, Dikeos DG, Kaneva R, Seretti A, Lilli A, Smeraldi E, Jakovljevic M, Folnegovic V, Rietscheli M, Milanova V, Valente F, Van Broeckhoven C, Mendlewicz J. 2002. Excess of allele 1 for α3 subunit GABA receptor gene (GABRA3) in bipolar patients: a multicentric association study. Mol Psychiatry 7:201–207.

Matsubara M, Suzuki S, Miura K, Terashima M, Sugita S, Kimura H, Hatsuda S, Mori T, Murakami H, Hayashi T, Ohta T, Ohara M. 2000. Electrophysiologic analysis of antidepressant drug effects on the GABA(A) receptor complex based upon antagonist-induced encephalographic power spectrum changes. Neuropsychobiology 42: 149–157.

Maurice T. 2004. Neurosteroids and sigma1 receptors, biochemical and behavioral relevance. Pharmacopsychiatry 37(Suppl 3): S171–S182.

McKinney WT. 2004. Overview of the past contributions in animal models and their changing place in psychiatry. Semin Clin Psychiatry 6:68–78.

Medina JH, Novas ML, Wolfman CN, Levi de Stein M, De Robertis E. 1983. Benzodiazepine receptors in rat cerebelar cortex and hippocampus undergo rapid and reversible changes after acute stress. Neuroscience 9:331–335.

Mei B, Li C, Dong S, Jiang CH, Wang H, Hu Y. 2005. Distinct gene expression profiles in hippocampus and amygdala after fear conditioning. Brain Res Bull 67:1–12.

Mervaala E, Kononen M, Fohr J, Husso-Saastamoinen M, Valkonen-Korhonen M, Kuikka JT, Viinamaki H, Tammi AK, Tiihonen J, Partanen J, Lehtonen J. 2001. SPECT and neuropsychological

performance in severe depression treated with ECT. J Affect Disord 66:47–58.

Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. 2003. Metabolic changes within the left dorsolateral prefrontal cortex occurring with electroconvulsive therapy in patients with treatment resistant unipolar depression. Psychol Med 33: 1277–1284.

Mihalek RM, Banerjee PK, Korpi ER, Quinlan JJ, Firestone LL, Mi ZP, Lagenaur C, Tretter V, Sieghart W, Anagnostaras SG. 1999. Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci USA 96:12905–12910.

Mindus P, Ericson K, Greitz T, Meyerson BA, Nyman H, Sjogren I. 1986. Regional cerebral glucose metabolism in anxiety disorders studied with positron emission tomography before and after psychosurgical intervention. A preliminary report. Acta Radiol Suppl 369:444–448.

MGI. 2006. Mouse Genome Informatics, http://www.informatics. jax.org/ Jackson Laboratory, Bar Harbor, ME.

Mohler H, Fritschy JM, Hensch T, Rudolph U. 2004. Specific GABAa circuits in brain development and therapy. Biochem Pharmacol 68:1685–1690.

Mombereau C, Kaupmann K, Froestl W, Sansig G, van der Putten H, Cryan JF. 2004. Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 29: 1050–1062.

Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JF. 2005. Altered anxiety and depression-related behaviors in mice lacking GABA-B(2) receptor subunits. Neuroreport 16:307–310.

Montpied P, Weizman A, Weizman R, Kook KA, Morrow AL, Paul SM. 1993. Repeated swim-stress reduces GABAA receptor alpha subunit mRNAs in the mouse hippocampus. Mol Brain Res 18: 267–272.

Morris JS, Friston KJ, Buchel C, Frith CD, Young AW, Calder AJ, Dolan RJ. 1998. A neuromodulatory role for the human amygdala in processing emotional facial expressions. Brain 121:47–57.

Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T. 1996a. Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 709: 215–220.

Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T. 1996b. Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 741: 240–245.

Nashold BC, Wilson WP, Slaughter DG. 1969. Sensations evoked by stimulation in the midbrain of man. J Neurosurg 30:14–24.

Nemeroff CB. 2003. The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37: 133–146.

Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Greshenfeld HK, Hen R, Koester S, Lederhendler I, Meaney M, Robbins T, Winsky L, Zalcman S. 2002. Preclinical models: status of basic research in depression. Biol Psychiatry 52:503–528.

Neumeister A, Wood S, Bonne O, Nugent AC, Luckenbaugh DA, Young T, Bain EE, Charney DS, Drevets WC. 2005. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry 57:935–937.

Nishimura H, Tanaka M. 1992. Effects of alprazolam on anxiety-related behavior of rats in a modified forced-swim test employing straw suspension. Pharmacol Biochem Behav 41:425–427.

Nishimura H, Ida Y, Tsuda A, Tanaka M. 1989. Opposite effects of diazepam and beta-CCE on immobility and straw-climbing behavior of rats in a modified forced-swim test. Pharmacol Biochem Behav 33:227–231.

Nobre MJ, Brandao ML. 2004. Analysis of freezing behavior and ultrasonic vocalization in response to foot-shocks, ultrasound signals and GABAergic inhibition in the inferior colliculus: effects of muscimol and midazolam. Eur Neuropsychopharmacol 14:45–52.

Nutt D. 2000. Treatment of depression and concomitant anxiety. Eur Neuropsychopharmacol 10(Suppl 4):S433–S437.

Nutt DJ. 2001. Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62(Suppl 11):22–27.

Nutt DJ. 2005. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 10:49–56.

Nutt DJ, Malizia AL. 2001. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396.

Nutt DJ, Ballenger JC, Sheehan D, Wittchen HU. 2002. Generalized anxiety disorder: comorbidity, comparative biology and treatment. Int J Neuropsychopharmacol 5:315–325.

Obrocea GV, Dunn RM, Frye MA, Ketter TA, Luckenbaugh DA, Leverich GS, Speer AM, Osuch EA, Jajodia K, Post RM. 2002. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 51:253–260.

O'Connor WT, Earley B, Leonard BE. 1985. Antidepressant properties of the triazolobenzodiazepines alprazolam and adinazolam: studies on the olfactory bulbectomized rat model of depression. Br J Clin Pharmacol 19(Suppl 1):49S–56S.

Olsen RW, Sapp DM. 1995. Neuroactive steroid modulation of GABAA receptors. Adv Biochem Psychopharmacol 48:57–74.

Olsen RW, Sapp DM, Bureau MH, Turner DM, Kokka N. 1991. Allosteric actions of central nervous system depressants including anesthetics on subtypes of the inhibitory gamma-aminobutyric acid A receptor-chloride channel complex. Ann N Y Acad Sci 625:145–154.

Olsen RW, Chang CS, Li G, Hanchar HJ, Wallner M. 2004. Fishing for allosteric sites on GABA(A) receptors. Biochem Pharmacol 68:1675–1684.

Ong J, Kerr DI. 2005. Clinical potential of GABA(B) receptor modulators. CNS Drug Rev 11:317–334.

Oruc L, Verheyen GR, Furac I, Ivezic S, Jakovljevic M, Raeymaekers P, Van Broeckhoven C. 1997. Positive association between the GABRA5 gene and unipolar recurrent major depression. Neuropsychobiology 36:62–64.

O'Sullivan K. 1984. Depression and its treatment in alcoholics: a review. Can J Psychiatry 29:379–384.

Pandossio JE, Molina VA, Brandao ML. 2000. Prior electrical stimulation of the inferior colliculus sensitizes rats to the stress of the elevated plus-maze test. Behav Brain Res 109:19–25.

Papadimitriou GN, Dikeos DG, Karadima G, Avramopolous D, Daskalopoulou EG, Vassilopoulos D, Stefanis CN. 1998. Association between the GABAA receptor α5 subunit gene locus (GABRA5) and dipolar affective disorder. Am J Med Genet 81:73–80.

Petty F. 1995. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 34:275–281.

Petty F, Sherman AD. 1981. GABAergic modulation of learned helplessness. Pharmacol Biochem Behav 15:567–570.

Petty F, Kramer GL, Dunnam D, Rush AJ. 1990. Plasma GABA in mood disorders. Psychopharmacol Bull 26:157–161.

Petty F, Kramer GL, Fulton M, Moeller FG, Rush AJ. 1993. Low plasma GABA is a trait-like marker for bipolar illness. Neuropsychopharmacology 9:125–132.

Petty F, Trivedi MH, Fulton M, Rush AJ. 1995. Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38:578–591.

Phelps EA, O'Connor KJ, Gatenby C, Gore JC, Grillon C, Davis M. 2001. Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci 4:437–441.

Pilc A, Nowak G. 2005. GABAergic hypotheses of anxiety and depression: Focus on GABA(B) receptors. Drugs Today 41:755–766.

Post RM. 2004. Differing psychotropic profiles of anticonvulsants in bipolar and other psychiatric disorders. Clin Neurosci Res 4:9–30.

Post RM, Ketter TA, Joffe RT, Kramlinger KL. 1991. Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol 6:197–207.

Post RM, Denicoff KD, Frye MA, Dunn RT, Leverich GS, Osuch E, Speer A. 1998. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century. Neuropsychobiology 38:152–166.

Quirk GJ, Gehlert DR. 2003. Inhibition of the amygdala: key to pathological states? Ann N Y Acad Sci 985:263–272.

Raghavendra V, Kaur G, Kulkarni SK. 2000. Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation. Eur Neuropsychopharmacol 10:473–481.

Rago L, Kiivet RA, Adojaan A, Harro J, Allikmets L. 1990. Stress-protection action of beta-phenyl(GABA): involvement of central and peripheral type benzodiazepine binding sites. Pharmacol Toxicol 66:41–44.

Rajkowska G. 2003. Depression: what we can learn from postmortem studies. Neuroscientist 9:273–284.

Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA. 1999. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45:1085–1098.

Rapaport MH, Clary C, Fayyad R, Endicott J. 2005. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 162:1171–1178.

Rauch SL, van der Kolk BA, Fisler RE, Alpert NM, Orr SP, Savage CR, Fischman AJ, Jenike MA, Pitman RK. 1996. A symptom provocation study of posttraumatic stress disorder using positron emission tomography and script-driven imagery. Arch Gen Psychiatry 53:380–387.

Reddy DS. 2003. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol Sci 24:103–106.

Reddy DS, O'Malley BW, Rogawski MA. 2005. Anxiolytic activity of progesterone in progesterone receptor knockout mice. Neuropharmacology 48:14–24.

Ring HA, Crellin R, Kirker S, Reynolds EH. 1993. Vigabatrin and depression. J Neurol Neurosurg Psychiatry 56:925–928.

Rochet T, Tonon MC, Kopp N, Vaudry H, Miachon S. 1998. Evaluation of endozepine-like immunoreactivity in the frontal cortex of suicide victims. Neuroreport 9:53–56.

Rodgers RJ. 1997. Animal models of 'anxiety': where next? Behav Pharmacol 8:477–496.

Rodin E. 1958. Metrazol tolerance in a normal volunteer population; an investigation of the potential significance of abnormal findings. EEG Clin Neurophysiol Suppl 10:433–446.

Rodin E. 1970. Metrazol tolerance in a "normal" volunteer population. A ten year follow-up report. J Nerv Ment Dis 150:438–443.

Rogawski MA, Loscher W. 2004. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10:685–692.

Rosahl TW. 2003. Validation of GABAa receptor subtypes as potential drug targets by using genetically modified mice. Curr Drug Targets CNS Neurol Disord 2:207–212.

Rosenthal M. 2003. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 64:1245–1249.

Rossini D, Lucca A, Zanardi R, Magri L, Smeraldi E. 2005. Transcranial magnetic stimulation in treatment-resistant depressed patients: a double-blind, placebo-controlled trial. Psychiatry Res 137:1–10.

Rosso IM, Cintron CM, Steingard RJ, Renshaw PF, Young AD, Yurgelun-Todd DA. 2005. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry 57:21–26.

Roy A. 1991. Cerebrospinal fluid diazepam binding inhibitor in depressed patients and normal controls. Neuropharmacology 30:1441–1444.

Roy A, DeJong J, Lamparski D, George T, Linnoila M. 1991. Depression among alcoholics. Relationship to clinical and cerebrospinal fluid variables. Arch Gen Psychiatry 48:428–432.

Roy MA, Neale MC, Pedersen NL, Mathe AA, Kendler KS. 1995. A twin study of generalized anxiety disorder and major depression. Psychol Med 25:1037–1049.

Rudolph U, Mohler H. 2006. GABA-based therapeutic approaches: GABAa receptor subtype functions. Curr Opin Pharmacol 6:1–6.

Rupniak NM. 2003. Animal models of depression: challenges from a drug development perspective. Behav Pharmacol 14:385–390.

Rupprecht R. 2003. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties. Psychoneuroendocrinology 28:139–168.

Sajdyk TJ, Shekhar A. 2000. Sodium lactate elicits anxiety in rats after repeated GABA receptor blockade in the basolateral amygdala. Eur J Pharmacol 394:265–273.

Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. 1999. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56:1043–1047.

Sanacora G, Mason GF, Krystal JH. 2000. Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. Crit Rev Neurobiol 14:23–45.

Sanacora G, Mason GF, Rothman DL, Krystal JH. 2002. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159:663–665.

Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH. 2003. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 160:577–579.

Sanacora G, Fenton LR, Fasula MK, Rothman DL, Levin Y, Krystal JH, Mason GF. 2006. Cortical gamma-aminobutyric acid concentrations in depressed patients receiving cognitive behavioral therapy. Biol Psychiatry 59:284–286.

Sand PG, Godau C, Riederer P, Peters C, Franke P, Nothen MM, Stober G, Fritze J, Maier W, Propping P, Lesch KP, Riess O, Sander T, Beckmann H, Deckert J. 2000. Exonic variants of the GABA(B) receptor gene and panic disorder. Psychiatr Genet 10:191–194.

Sandford JJ, Argyropoulos SV, Nutt DJ. 2000. The psychobiology of anxiolytic drug. 1. Basic neurobiology. Pharmacol Ther 88:197–212.

Sands SA, Reisman SA, Enna SJ. 2004. Effect of antidepressants on GABA(B) receptor function and subunit expression in rat hippocampus. Biochem Pharmacol 68:1489–1495.

Sarup A, Larsson OM, Schousboe A. 2003. GABA transporters and GABA-transaminase as drug targets. Curr Drug Target CNS Neurol Disord 2:269–277.

Saylam C, Ucerler H, Kitis O, Ozand E, Gonul AS. 2006. Reduced hippocampal volume in drug-free depressed patients. Surg Radiol Anat 28:82–87.

Schaller JL, Thomas J, Rawlings D. 2004. Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed 6:8.

Schaffer LC, Schaffer CB, Howe J. 2002. An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 71:259–263.

Schechter MD, Chance WT. 1979. Non-specificity of "behavioral despair" as an animal model of depression. Eur J Pharmacol 60:139–142.

Schenber LC, Graeff FG. 1978. Role of the periaqueductal gray substance in the antianxiety action of benzodiazepines. Pharmacol Biochem Behav 9:287–295.

Schmitt U, Hiemke C. 1999. Effects of GABA-transporter (GAT) inhibitors on rat behavior in open field and elevated plus maze. Behav Pharmacol 10:131–137.

Schmitt U, Luddens H, Hiemke C. 2002. Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. J Neural Transm 109:871–880.

Schousboe A, Sarup A, Larsson OM, White HS. 2004. GABA transporters as drug targets for modulation of GABAergic activity. Biochem Pharmacol 68:1557–1563.

Schwartz TL. 2002. The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol Bull 36:53–57.

Sen S, Villafuerte S, Nesse R, Stoltenberg SF, Hopcian J, Cleiberman L, Weder A, Burmeister M. 2004. Serotonin transporter and GABAA alpha 6 receptor variants are associated with neuroticism. Biol Psychiatry 55:244–249.

Shah AA, Sjovold T, Treit D. 2004. Inactivation of the medial prefrontal cortex with the GABAA receptor agonist muscimol increases open-arm activity in the elevated plus-maze and attenuates shock-probe burying in rats. Brain Res 1028:112–115.

Shekhar A, Keim SR, Simon JR, McBride WJ. 1996. Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55:249–256.

Sheline YI. 2003. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54:338–352.

Shelton RC. 2003. Treating bipolar depression. J Fam Pract Suppl S14–S17.

Shephard RA, Wedlock P, Wilson NE. 1992. Direct evidence for mediation of an anticonflict effect of baclofen by GABAb receptors. Pharmacol Biochem Behav 41:651–653.

Sherif F, Oreland L. 1995. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behavior in socially isolated rats. Behav Brain Res 72:135–140.

Shiah IS, Yatham LN. 1998. GABA function in mood disorders: an update and critical review. Life Sci 63:1289–1303.

Shibata S, Nakanishi H, Watanabe S, Ueki S. 1984. Effects of chronic administration of antidepressants on mouse-killing behavior (muricide) in olfactory bulbectomized rats. Pharmacol Biochem Behav 21:225–230.

Sieghart W. 1995. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev 47: 181–234.

Sieghart W, Fuchs K, Tretter V, Ebert V, Jechlinger M, Hoger H, Adamiker D. 1999. Structure and subunit composition of GABA(A) receptors. Neurochem Int 34:379–385.

Singewald N, Salchner P, Sharp T. 2003. Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53:275–283.

Skrebuhhova T, Allikmets L, Matto V. 1999. Effects of anxiogenic drugs in rat forced swimming test. Methods Find Exp Clin Pharmacol 21:173–178.

Smoller JW, Rosenbaum JF, Biederman J, Susswein LS, Kennedy J, Kagan J, Snidman N, Laird N, Tsuang MT, Faraone SV, Schwarz A, Slaugenhaupt SA. 2001. Genetic association analysis of behavioral inhibition using candidate loci from mouse models. Am J Med Genet 105:226–235.

Spivak B, Maayan R, Kotler M, Mester R, Gil-Ad I, Shtaif B, Weizman A. 2000. Elevated circulatory level of GABA(A)—antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. Psychol Med 30:1227–1231.

Stahl SM. 2004. Anticonvulsants as anxiolytics. 1. Tiagabine and other anticonvulsants with actions on GABA. J Clin Psychiatry 65:291–292.

Stork O, Ji FY, Kaneko K, Stork S, Yoshinobu Y, Moriya T, Shibata S, Obata K. 2000. Postnatal development of a GABA deficit and disturbance of neural functions in mice lacking GAD65. Brain Res 865:45–58.

Stork O, Ji FY, Obata K. 2002. Reduction of extracellular GABA in the mouse amygdala during and following confrontation with a conditioned fear stimulus. Neurosci Lett 327:138–142.

Strakowski SM, Adler CM, DelBello MP. 2002. Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? Bipolar Disord 4:80–88.

Strohle A, Romeo E, Hermann B, Pasini A, Spalletta G, di Michele F, Holsboer F, Rupprecht R. 1999. Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 45:274–277.

Sundman I, Allard P, Eriksson A, Marcusson J. 1997. GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 35:11–15.

Sundman-Eriksson I, Allard P. 2002. (^{3}H)Tiagabine binding to GABA transporter-1 (GAT-1) in suicidal depression. J Affect Disord 71:29–33.

Sundstrom I, Ashbrook D, Backstrom T. 1997. Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology 22:25–38.

Sundstrom-Poromaa I, Smith S, Gulinello M. 2003. GABA receptors, progesterone and premenstrual dysphoric disorder. Arch Women Ment Health 6:23–41.

Szymczyk G, Zebrowska-Lupina I. 2000. Influence of antiepileptics on efficacy of antidepressant drugs in forced swimming test. Pol J Pharmacol 52:337–344.

Tanay VAMI, Glencorse TA, Greenshaw AJ, Baker GB, Bateson AN. 1996. Chronic administration of antipanic drugs alters rat brainstem GABAa receptor subunit mRNA levels. Neuropharmacology 35:1475–1482.

Tanay VAMI, Greenshaw AJ, Baker GB, Bateson AN. 2001. Common effects of chronically administered antipanic drugs on brainstem GABAA receptor subunit gene expression. Mol Psychiatry 6:404–412.

Tunnicliff G, Malatynska E. 2003. Central GABAergic systems and depressive illness. Neurochem Res 28:965–976.

Turner DM, Ransom RW, Yang JS, Olsen RW. 1989. Steroid anesthetics and naturally occurring analogs modulate the gamma-aminobutyric acid receptor complex at a site distinct from barbiturates. J Pharmacol Exp Ther 248:960–966.

Uhart M, McCaul ME, Oswald LM, Choi L, Wand GS. 2004. GABRA6 gene polymorphism and an attenuated stress response. Mol Psychiatry 9:998–1006.

Umezu T. 1999. Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol 80:111–118.

Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. 2000. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology (Berl) 148:336–343.

Urani A, Roman FJ, Phan VL, Su TP, Maurice T. 2001. The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 298:1269–1279.

Urani A, Chourbaji S, Gass P. 2005. Mutant mouse models of depression: candidate genes and current mouse lines. Neurosci Biobehav Rev 29:805–828.

Uzunov DP, Cooper TB, Costa E, Guidotti A. 1996. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography. Proc Natl Acad Sci USA 93: 12599–12604.

Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A. 1998. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95: 3239–3244.

Uzunova V, Ceci M, Kohler C, Uzunov DP, Wrynn AS. 2003. Region-specific dysregulation of allopregnanolone brain content in the olfactory bulbectomized rat model of depression. Brain Res 976: 1–8.

Uzunova V, Wrynn AS, Kinnunen A, Ceci M, Kohler C, Uzunov DP. 2004. Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur J Pharmacol 486:31–34.

Vaiva G, Thomas P, Ducrocq F, Fontaine M, Boss V, Devos P, Rascle C, Cottencin O, Brunet A, Laffargue P, Goudemand M. 2004. Low posttrauma GABA plasma levels as a predictive factor in the development of acute posttraumatic stress disorder. Biol Psychiatry 55: 250–254.

Vekovisheva OYu. 2003. The role of a6 subunit-containing GABAa receptors in behavioral effects of alcohol and drug treatments. Acta Univer Tamper 928:1–58.

Verkuyl JM, Hemby SE, Joels M. 2004. Chronic stress attenuates GABAergic inhibition and alters gene expression of parvocellular neurons in rat hypothalamus. Eur J Neurosci 20:1665–1673.

Villafuerte S, Burmeister M. 2003. Untangling genetic networks of panic, phobia, fear and anxiety. Genome Biol 4:224.1–4.

Wang PW, Ketter TA. 2005. Clinical use of carbamazepine for bipolar disorders. Expert Opin Pharmacother 6:2887–2902.

Wang H, Zhu YZ, Wong PTH, Farook JM, Teo AL, Lee LKH, Moochhala S. 2003. cDNA microarray analysis of gene expression in anxious PVG and SD rats after cat-freezing test. Exp Brain Res 149: 413–421.

Weizman R, Weizman A, Kook KA, Vocci F, Deutsch SI, Paul SM. 1989. Repeated swim stress alters brain benzodiazepine receptors measured in vivo. J Pharmacol Exp Ther 249:701–707.

Whiting PJ. 2003. GABA-A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov Today 8: 445–450.

Wik G, Fredrikson M, Ericson K, Eriksson L, Stone-Elander S, Greitz T. 1993. A functional cerebral response to frightening visual stimulation. Psychiatry Res 50:15–24.

Williams SM, Bryan-Lluka LJ, Pow DV. 2005. Quantitative analysis of immunolabeling for serotonin and for glutamate transporters after administration of imipramine and citalopram. Brain Res 1042: 224–232.

Wong ML, Licinio J. 2004. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3:136–151.

Wu JC, Buchsbaum MS, Hershey TG, Hazlett E, Sicotte N, Johnson JC. 1991. PET in generalized anxiety disorder. Biol Psychiatry 29: 1181–1199.

Yamada K, Watanabe A, Iwayama-Shigeno Y, Yoshikawa T. 2003. Evidence of association between γ-aminobutyric acid type A receptor genes located on 5q34 and female patients with mood disorders. Neurosci Lett 349:9–12.

Yang J, Shen J. 2005. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine. Neuroscience 135:927–937.

Yilmazer-Hanke DM, Roskoden T, Zilles K, Schwegler H. 2003. Anxiety-related behavior and densities of glutamate, GABAA, acetylcholine and serotonin receptors in the amygdala of seven inbred mouse strains. Behav Brain Res 145:145–159.

Yoshikawa T, Watanabe A, Ishitsuka Y, Nakaya A, Nakatani N. 2002. Identification of multiple genetic loci linked to the propensity for "behavioral despair" in mice. Genome Res 12:357–366.

Yurgelun-Todd DA, Gruber SA, Kanayama G, Killgore WD, Baird AA, Young AD. 2000. fMRI during affect discrimination in bipolar affective disorder. Bipolar Disord 2:237–248.

Zarrindast M, Rostami P, Sadeghi-Hariri M. 2001. GABA(A) but not GABA(B) receptor stimulation induces antianxiety profile in rats. Pharmacol Biochem Behav 69:9–15.

Zhang L, Rubinow DR, Ma W, Marks JM, Feldman AN, Barker JL, Tathan TA. 1998. GABA receptor subunit mRNA expression in brain of conflict, yoked control and control rats. Mol Brain Res 58: 16–26.

Zimmerberg B, Brunelli SA, Fluty AJ, Frye CA. 2005. Differences in affective behaviors and hippocampal allopregnanolone levels in adult rats of lines selectively bred for infantile vocalizations. Behav Brain Res 159:301–311.

Zwanzger P, Rupprecht R. 2005. Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci 30:167–175.